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  1 
Summary 
Post-translational modifications (PTMs) of proteins regulate their structure, 
cellular localization and function. ADP-ribosylation is a PTM catalyzed by ADP-
ribosyltransferases (ARTs), which attach one (mono-ADP-ribose, MAR) or several 
(poly-ADP-ribose, PAR) consecutive ADP-ribose moieties from NAD+ onto a 
protein. ADP-ribosylation is involved in various cellular stress responses and human 
pathologies such as cancer, inflammatory and neurodegenerative diseases. 
Understanding how proteins are ADP-ribosylated and again demodified is crucial for 
understanding the molecular mechanisms underlying these disease processes. The 
known nuclear ADP-ribose acceptor amino acids are arginine, lysine, glutamic and 
aspartic acid and serine, with serine being the most prominent one. Degradation of 
PAR is catalyzed by poly-ADP-glycohydrolase (PARG) and ADP-ribosylhydrolase 3 
(ARH3). In contrast, ARH1, macrodomain-containing proteins 1 and 2 (MACROD1, 
MACROD2) and C6ORF130 degrade MAR linked to arginine or aspartic and 
glutamic acid, respectively. However, an enzyme capable of releasing MAR from 
serines has so far not been described. Therefore, the aim of this thesis was to identify 
and characterize an enzyme capable of hydrolyzing the ADP-ribose-serine linkage in 
vitro and in vivo.  
Using state of the art in vitro modification assays and mass spectrometry, we 
identified ARH3 as a novel serine-mono-ARH in vitro and in vivo that localized to 
chromatin. ARH3 knockout (KO) MEFs showed an increase in total ADP-ribosylated 
proteins compared to wild type MEFs under basal conditions and upon oxidative 
stress induced by H2O2. ARH3 KO mice were viable, fertile and exhibited largely a 
WT phenotype except for a body weight gain in females observed upon aging. 
Western blot and mass spectrometric analysis revealed an increase in MARylated 
proteins particularly in the spleen of ARH3 KO animals. Many of the identified 
putative ARH3 targets within the spleen were nuclear proteins involved in DNA- and 
RNA-associated processes.  
Together, these results revealed that ARH3 is the only enzyme known to date 
that hydrolyzes both PAR and MAR attached to serine residues. Our data suggest 
ARH3 as an important regulator of nuclear ADP-ribosylation turnover and main 
opponent of ADP-ribosyltransferase diphtheria-toxin 1 (ARTD1), the major enzyme 
responsible for serine-ADP-ribosylation in the nucleus. 
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Zusammenfassung 
Die Struktur, zelluläre Lokalisation und Funktion von Proteinen wird durch 
Posttranslationale Modifikationen (PTMs) reguliert. ADP-Ribosylierung ist eine 
PTM, welche durch ADP-Ribosyltransferasen (ARTs) katalysiert wird und NAD+ als 
Substrat benötigt. Bei der Reaktion werden eine (Mono-ADP-Ribose, MAR) oder 
mehrere ADP-Ribosegruppen (Poly-ADP-Ribose, PAR) an ein Protein gebunden. Die 
ADP-Ribosylierung ist an verschiedenen zellulären Stressantworten und 
Humanpathologien wie Krebs, entzündlichen und neurodegenerativen Erkrankungen 
beteiligt. Das Verständnis, wie Proteine ADP-ribosyliert und wieder demodifiziert 
werden, ist entscheidend für das Verständnis der molekularen Mechanismen, welche 
diesen Krankheitsprozessen zugrundeliegen. Im Zellkern findet man ADP-ribosylierte 
Arginine, Lysine, Glutamin- und Asparaginsäuren sowie, am häufigsten, Serine. Der 
Abbau von PAR wird durch Poly-ADP-Glycohydrolase (PARG) und ADP-
Ribosylhydrolase 3 (ARH3) katalysiert, wohingegen ARH1, die Makrodomänen-
Proteine 1 und 2 (MACROD1, MACROD2) und C6ORF130 MAR entfernen, welche 
an Arginin beziehungsweise Asparagin- und Glutaminsäure gebunden ist. Bisher ist 
jedoch kein Enzym bekannt, das MARylierte Serine demodifiziert. Ziel dieser Arbeit 
war es daher, ein solches Enzym zu identifizieren und zu charakterisieren. 
Mittels in vitro Modifikationsassays und Massenspektrometrie wurde ARH3 
in vitro und in vivo neu als Serin-Mono-ARH im Zellkern identifiziert. ARH3-
Knockout (KO) MEFs zeigten einen Anstieg der gesamten ADP-ribosylierten 
Proteine im Vergleich zu WT MEFs, sowohl unter basalen Bedingungen als auch 
während H2O2-induziertem oxidativem Stress. ARH3 KO Mäuse waren lebensfähig, 
fruchtbar und hatten einen vergleichbaren Phänotyp wie WT Mäusen, mit Ausnahme 
einer altersbedingten Gewichtszunahme bei Weibchen. Western Blot und 
massenspektrometrische Analysen zeigten einen Anstieg an MARylierten Proteinen 
vor allem in der Milz von ARH3 KO Tieren. Viele dieser Proteine sind im Zellkern 
lokalisiert und an DNA- und RNA-assoziierten Prozessen beteiligt.  
Zusammenfassend zeigten diese Ergebnisse, dass ARH3 das einzige bisher 
bekannte Enzym ist, das ADP-Ribose vollständig von Serinen entfernt. Unsere Daten 
deuten darauf hin, dass ARH3 ein wichtiger Regulator von ADP-Ribosylierung im 
Zellkern ist und als Antagonist der ART Diphtherie-Toxin 1 (ARTD1) wirkt, dem 
Hauptenzym verantwortlich für Serin-ADP-Ribosylierung im Zellkern. 
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1 Introduction 
1.1 ADP-ribosylation 
In both eukaryotic and prokaryotic organisms, the DNA encodes genes, which 
upon transcription and translation give rise to intra- and extracellular proteins. The 
complexity of a single cell or an entire organism is enhanced by various regulatory 
mechanisms on the DNA and mRNA level, which include initiation of transcription at 
alternative promoters, differential termination, or alternative splicing of a certain 
transcript. Additionally, one important way of introducing a certain complexity to a 
cell on the protein level is a post-translational modification (PTM).  
PTMs include the addition of one or several chemical groups, e.g. methyl- or 
acetyl-groups, as well as the attachment of small proteins, such as ubiquitin or small 
ubiquitin-related modifier (SUMO), onto targets. These modifications have been 
shown to impact different properties of a protein, ranging from structural to functional 
changes. PTMs allow a cell to quickly react to external and internal cues as compared 
to e.g. changes in transcription, or splicing1.  
As opposed to rather small modifications, such as methylation or acetylation, 
the modification discussed in this thesis, ADP-ribosylation, is a rather bulky 
modification, harboring two negative charges per unit of ADP-ribose (Figure 1).  
 
 
Figure 1: Structure of ADP-ribose in its monomeric and polymeric form. Taken from2.   
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It is thus not surprising that adding ADP-ribose in either a monomeric or 
polymeric form influences a wide array of cellular functions, such as DNA repair and 
transcription, and is at work in various pathological processes including inflammatory 
and antiviral responses3.  
The earliest reports of ADP-ribosylation date back to the mid 1960s, where 
poly-ADP-ribose (PAR) was first detected in nuclei of mammalian cells4. Soon after, 
the attachment of mono-ADP-ribose (MAR) onto mammalian proteins by bacterial 
toxins was discovered5. Since these first findings, various research groups have 
worked on the identification of the writers, readers and erasers of ADP-ribosylation, 
as well as the targeted proteins and the respective amino acid acceptor sites, which 
will be discussed in more detail below.  
 
1.2 Writers of ADP-ribosylation 
All enzymes with the capability of synthesizing MARylation or PARylation 
consume nicotinamide adenine dinucleotide (NAD+). NAD+ is an abundant cellular 
metabolite, and functions in various pathways6. Its main role lies in energy 
metabolism, where NAD+ forms the reducing agent NADH upon accepting two 
electrons, thereby fueling the mitochondrial electron transport chain7. Synthesis of 
NAD+ can happen either de novo, which requires tryptophan uptake through food, or 
via various salvage pathways, where nicotinic acid (NA), nicotinamide (NAM), or 
nicotinamide riboside (NR) are taken up and further catalyzed by the enzymes 
nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide mononucleotide 
adenylyltransferase (NMNAT)8.  
The main families synthesizing extracellular and intracellular MAR and PAR 
are Clostridium toxin- and diphtheria toxin-like ARTs (ARTCs and ARTDs, 
respectively). They use the ADP-ribose moiety of NAD+ and attach it to their targets. 
Writers of ADP-ribosylation compete for cellular NAD+ with other enzymes. E.g. 
cyclic ADP-ribose (cADPR), a messenger molecule important in calcium signaling, is 
produced by cADPR synthases, which also use NAD+ as a substrate9. Sirtuins require 
NAD+ as a co-substrate for the deacetylation of lysines (or removal of larger PTMs 
such as malonyl- and succinyl-groups) by transfer of the acetyl group to the ADP-
ribose of NAD+10. Some sirtuins have recently been shown to be capable of using the 
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ADP-ribose moiety of NAD+ to act as ADP-ribosyltransferases (ART) as well, but 
will not be discussed further10.  
 
ADP-ribosyltransferases, clostridium toxin-like (ARTCs) 
The ARTC family is characterized by sequence homology to clostridium toxin 
and its members are membrane-bound and act extracellularly11. ARTCs have been 
shown to specifically mono-ADP-ribosylate arginines (R), and the amino acid motif 
arginine-serine-glutamic acid (R-S-E) in the catalytic cleft is necessary for this 
activity12. In human tissue, mRNAs for ARTC1, 3, 4, and 5 are expressed, whereas in 
mice, mRNAs from ARTC1-5 are identified13.  
Enzymatic activity has been shown for ARTC1, 2, and 5, while ARTC3 and 4 
are inactive, presumably due to the lack of the aforementioned catalytic R-S-E triad. 
Interestingly, the analysis of mRNA expression patterns for the enzymatically active 
ARTCs revealed tissue-specific expression, with ARTC1 being abundant in muscle 
and cardiac cells, and ARTC5 in testes13.  
 
ADP-ribosyltransferases, diphtheria toxin-like (ARTDs) 
The ARTD family is characterized by homology to diphtheria toxin and 
catalyzes intracellular ADP-ribosylation11. Which ARTD modifies which amino acid 
is so far largely unknown (see further below). Catalytically active ARTDs harbor a 
different triad in the catalytic cleft compared to ARTCs, namely histidine-tyrosine-
glutamic acid (H-Y-E)11. A total of 18 different members have been identified in 
humans (Table 1).  
 
Table 1: ARTD family members: Activity taken from14, localization information retrieved from 
www.proteinatlas.org, table continues on the next page. 
New 
nomenclature 
Old 
nomenclature Activity 
Localization in unstimulated 
cells 
ARTD1 PARP1 PAR Nucleus 
ARTD2 PARP2 PAR Nucleus, nucleoli 
ARTD3 PARP3 MAR Nucleoli, cytosol 
ARTD4 PARP4, vPARP MAR Cytosol 
ARTD5 PARP5a, TNKS PAR Nucleoplasm, nuclear membrane 
ARTD6 PARP5b, TNKS2 PAR Microtubules 
ARTD7 PARP15, BAL1 MAR Mitochondria 
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In contrast to ARTCs, ARTD1, 2, 5, and 6 are capable of producing not only 
monomeric ADP-ribosylation, but can form linear or branched chains of PAR15.  The 
other family members are thought to either be inactive, due to a lack of the catalytic 
H-Y-E triad, or known to catalyze MAR16. Interestingly, besides their catalytic 
domain, ARTDs carry various other domains, e.g. RNA-recognition motifs, macro-
domains which bind ADP-ribose, zinc finger domains known to bind DNA, to name 
just a few11. These domains regulate various aspects of the respective ARTD family 
member, such as intracellular localization, target binding, activation and function.   
 
ADP-ribose amino acid acceptor sites 
For a long time, the potential amino acids to be modified by ARTDs were 
thought to be aspartic (D) and glutamic acids (E) (via an ester linkage), as well as 
lysines (K) and arginines (R) (via a ketoamine linkage).  
One approach used to identify ADP-ribosylated sites is the reanalysis of 
already existing phosphoproteomics data, because the phosphopeptide enrichment 
protocols potentially also isolate ADP-ribosylated peptides. Indeed, intracellular 
targets modified at Rs were identified by this approach17.  
Recently, new ADP-ribosylation enrichment protocols and mass spectrometric 
techniques emerged which allow the direct detection of ADP-ribosylated peptides. 
Mass spectrometric analysis of the so far most studied PAR writer ARTD1 and its 
targets provided evidence for the ADP-ribosylation of Ds, Es, and Ks in vitro18-20. 
ARTD8 PARP14, COAST6, BAL2 MAR Cytosol 
ARTD9 PARP9, BAL1 MAR Nucleoplasm, cytosol, mitochondria 
ARTD10 PARP10 MAR Nucleoli, cytosol 
ARTD11 PARP11 MAR Not available 
ARTD12 PARP12 MAR Nucleus 
ARTD13 PARP13, ZAP, ZC3HDC1 
Presumably 
inactive Cytosol, Golgi 
ARTD14 PARP7, TIPARP MAR Uncertain 
ARTD15 PARP16 MAR Not available 
ARTD16 PARP8 MAR Nucleoplasm, cytosol 
ARTD17 PARP6 MAR Plasma membrane 
ARTD18 TPT1 Presumably inactive Cytosol 
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ARTD10, the best-known MAR writer, auto- and trans-ADP-ribosylated acidic 
amino acid residues Ds and Es21.  
Proteome-wide analysis using boronate-affinity chromatography for enriching 
ADP-ribosylated peptides confirmed Ds and Es to be modified in vivo22. An 
enrichment method using Af1521, a protein from Archaeglobus fulgidus with high 
affinity for ADP-ribose, has recently been established as a tool for enriching ADP-
ribosylated proteins and peptides and can be used in combination with mass 
spectrometry to identify tissue- and cell-specific ADP-ribosylomes, confirming Ds, 
Es, Ks and Rs as ADP-ribose acceptor sites23,24.   
The accuracy of this data has recently been challenged by the development of 
more precise and reliable mass spectrometry methods, which revealed that the most 
prominently ARTD-modified sites in vivo are serines25-27.  
 
1.3 Readers of ADP-ribosylation 
As for other protein modifications, ADP-ribose binding proteins are necessary 
to recognize and translate an ADP-ribose mark into a signal and are, thus, so called 
readers of ADP-ribosylation (Figure 2).  
 
Figure 2: Readers of PAR. Binding modules and their respective binding site are shown, 
multi-branched arrows indicate that the binding sites have so far not been identified. Taken 
from28. 
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Macrodomain 
The macrodomain is a rather large domain of around 130-190 amino acids, 
and got its name by homology to the core histone macroH2A, whose non-histone 
sequence is a macrodomain29. The macrodomain has been shown to have high affinity 
for ADP-ribose and binds both MAR and the terminal ADP-ribose moiety of PAR30. 
To date, eleven human proteins have been identified to have one or more 
macrodomains, including several ARTs, namely ARTD7, ARTD8, and ARTD9, as 
well as the proteins macrodomain containing 1 and 2 (MACROD1, MACROD2) and 
terminal ADP-ribose glycohydrolase (TARG, also C6ORF130)31. The latter three 
have been found to possess macrodomains with hydrolase activity, which will be 
discussed in more detail below21,32,33. Having binding ability and in some cases 
enzymatic activity against MAR makes the macrodomain a versatile module. The 
macrodomain-containing protein Af1521 from Archaeglobus fulgidus has recently 
been established as a tool for enriching ADP-ribosylated proteins and peptides for 
instance for mass spectrometry approaches to identify tissue- and cell-specific ADP-
ribosylomes23,24. In contrast to the other known ADP-ribose binding domains, the 
macrodomain is the only one binding MAR. 
 
WWE 
The WWE domain contains around 90 amino acids and is named after its 
conserved amino acid triad consisting of two tryptophans (W) and one E. The WWE 
domain exclusively binds to PAR, as it recognizes iso-ADP-ribose, a structure unique 
for two consecutively bound ADP-ribose units in a linear PAR chain34. The few 
proteins found to possess a WWE domain can be categorized as either ARTD or 
ubiquitin ligase family members, pointing towards a potential interplay of the two 
PTM systems35. Similar to the macrodomain, the WWE domain has recently been 
used as a biotechnological tool, in this case to establish a chromatin affinity 
purification (ChAP) protocol to identify ADP-ribosylated loci in the genome36. 
 
Poly-ADP-ribose-binding motif (PBM) 
The PBM has been identified as an around 20 amino acid long consensus 
sequence containing a hydrophobic stretch37. It is unknown which exact part of the 
PAR chains the PBM binds to. With the development of more advanced 
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bioinformatics tools, several hundred proteins with a potential PBM have been 
identified38. No other PAR binder is equally well represented in the proteome. 
Functionally, the PBM is present in proteins involved in DNA repair, replication and 
chromatin remodeling, as well as in cell cycle regulation and RNA binding38.  
 
PAR-binding zinc finger (PBZ) 
The PBZ is an around 30 amino acid long stretch39. It binds to two ADP-ribose 
units in a PAR chain, the so-called ADP-ribose-ADP-ribose junction39,40. The PBZ 
was found in two proteins so far, APFL and CHFR, suggesting a specialized role of 
this binding domain in non-homologous end- joining (NHEJ) and cell cycle control, 
respectively41. Checkpoint kinase 1 (CHK1) contains a potential variation of the PBZ 
allowing PAR binding42. The presence of other PBZ-containing proteins is unknown.  
 
FHA and BRCT domains 
The fork-head associated (FHA) or breast cancer 1 C-terminal (BRCT) 
domains span around 90 amino acids. Formerly known to bind phosphorylated 
targets, these domains have been shown to be capable of also recognizing ADP-
ribosylated proteins43. Similar to the PBM, the exact binding mode to PAR is missing 
so far. Various proteins have been identified to possess FHA or BRCT domains and 
all are found to function in DNA damage response pathways43.  
 
RNA- and DNA-binding domains 
PAR resembles nucleic acids in that it is highly negatively charged and 
contains phosphate and ribose groups. Considering this similarity, it is not surprising 
that recent studies revealed several domains and motifs so far mainly associated with 
DNA- or RNA-binding to also exhibit a certain affinity for PAR28. For most of these 
domains, their exact binding mode and functions are not known, and will therefore 
only be shortly introduced:  
• The most widely spread RNA-binding motif is the RNA recognition motif 
(RRM), with over 50’000 copies found in all domains of life44.   
• Serine/arginine repeats (SR) are mainly associated with SR proteins. Those are 
involved in the regulation of splicing, and additionally to their SR motif also 
contain an RRM45.   
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• Arginine- and glycine-rich regions (RGG) carry various positive charges 
which allow the binding to PAR46.  They are found abundantly in the human 
proteome46.  
• The oligonucleotide/oligosaccharide-binding fold (OB-fold) and the PilT N-
terminal (PIN) domain bind single-stranded nucleic acids and 
oligosaccharides, and were recently found to also bind PAR47,48.  
 
1.4 Erasers of ADP-ribosylation 
As opposed to the many known ARTs (described above), only a few proteins 
with hydrolytic activity towards the ADP-ribose bonds within PAR or the ADP-
ribose-amino acid linkage have been identified so far (Table 2)49.  
 
 
Table 2: Erasers of ADP-ribosylation. Activity taken from49, localization information retrieved from 
www.proteinatlas.org. 
Eraser 
Hydrolase 
activity 
(amino acid) 
Localization in unstimulated cells 
ARH1 MAR (R) Nuclear membrane, nucleus 
ARH2 Inactive Nucleoplasm 
ARH3 PAR Nucleoplasm 
MACROD1 MAR (D/E) Nucleoplasm 
MACROD2 MAR (D/E) Nucleus, nucleoli 
TARG (C4ORF130) PAR/MAR (D/E) Nucleus, nucleoli 
PARG PAR Nucleus, vesicles 
 
 
ARH family 
Around 30 years ago, the first mammalian hydrolase with the ability to reverse 
arginine-ADP-ribosylation has been purified from turkey erythrocytes50,51. The 39 kDa 
protein was later named ADP-ribosylhydrolase 1 (ARH1) and was the founder of the 
ARH family of ADP-ribosylhydrolases. In parallel, the bacterial protein 
dinitrogenase-activating glycohydrolase (DRAG) was identified as an arginine-
specific ARH regulating nitrogen fixation in Rhodospirillum rubrum52,53. Several 
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years later, bioinformatic searches identified three DRAG-homologous proteins in the 
mammalian genome, one of which was the already identified ARH1, and two 
additional proteins, ARH2 and ARH313. 
 
ARH1 
ARH1 specifically hydrolyzes the N-glycosidic bond linking the mono-ADP-
ribose to the guanidine group of arginine 54. In vitro, ARH1 has been shown to have a 
very weak hydrolase activity towards the O-glycosidic bond of PAR and 2’-O-acetyl 
adenosine diphosphate ribose (OAADPR), the metabolite released by sirtuins upon 
deacetylation of their respective targets55. However, due to the much higher activity of 
PARG and ARH3 on these substrates, this catalytic activity of ARH1 can probably be 
neglected in vivo. Other ADP-ribose-amino acid linkages synthesized by bacterial 
toxins, such as ADP-ribose-cysteine, -asparagine-, and diphthamide were resistant to 
ARH1 treatment56. ADP-ribose seems to be the only substrate for ARH1, as only 
ADP-ribose but no derivatives or structurally related molecules, e.g. ribose 5-
phosphate, adenosine monophosphate (AMP), adenosine diphosphate (ADP) or 
NAD+, inhibits its activity51,56.  
At position 60 and 61, the human ARH1 protein harbors two catalytically 
important aspartic acids, keeping two magnesium ions (Mg2+) in place, and when 
mutating these residues to alanine, enzymatic activity but not binding to ADPr is 
greatly reduced57. A recent study revealed several sites on ARH1 that are subject to 
phosphorylation and that phosphorylated ARH1 is more orderly structured58. 
Generation and investigation of an Arh1 knockout mouse revealed an essential 
function of ARH1 in the organismal response to cholera toxin, as both cells and 
intestinal loops isolated from knockout mice showed a higher sensitivity towards 
cholera toxin application59. ARH1 knockout animals were also shown to develop 
spontaneous lymphomas, adenocarcinomas and metastases more frequently than 
wildtype age-matched control animals, establishing ARH1 as a tumor suppressor60,61.  
 
ARH2 
ARH2 is the least studied member of the ARH family. ARH2 is presumably 
catalytically inactive, even though capable of binding ADP-ribose. Presumably, its 
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inactivity is due to the lack of the two catalytic aspartic acids present in both ARH1 
and ARH355.  
ARH2 is exclusively expressed in the heart of developing mammals, and 
recently, knockdown of all ARH2 variants in Xenopus laevis revealed that ARH2 is 
needed for myofibril assembly and both outgrowth and functionality of heart 
ventricles62.  
 
ARH3  
ARH3 degrades PAR via hydrolysis of the O-glycosidic bond56,63. 
Additionally, ARH3 efficiently hydrolyzes OAADPR55,64. This seems puzzling, as the 
high structural similarity to ARH1 would suggest ARH3 to have an activity towards 
mono-ADP-ribosylated Rs. However, neither activity towards MARylated Rs nor 
towards any bacterially caused MARylation could be experimentally confirmed56. As 
for ARH1, ARH3 activity is inhibited by ADPr, but not by ribose-5-phosphate, AMP, 
ADP, or NAD+56.  
Catalytic activity of ARH3 requires two Mg2+ ions, and the aspartic acid 
residues at position 77 and 78 of human ARH3 are thought to mediate the binding to 
these ions56,63. As for ARH1, mutation of these conserved residues abolishes catalytic 
activity of ARH356.  Several ARH3 mutants were generated in vitro and revealed 
various amino acids which are enzymatically and/or structurally important63. 
ARH3 is mainly found in the nucleus, but was also detected in the cytoplasm 
and mitochondria65. Functionally, ARH3 was found to be the main enzyme degrading 
mitochondrial PAR66. In another study focusing on oxidative stress, ARH3 has also 
been found to play a protective role in that its enzymatic activity degrades PAR, 
thereby inhibiting PAR-dependent cell death (parthanatos)65. Even though mouse 
embryonic fibroblasts from Arh3 knockout mice were used in the previous studies, no 
phenotypic data has been published so far. In humans, the expression of ADPRHL2 
(gene name of ARH3) correlates with decreased survival of breast cancer patients67. 
 
Macrodomain-containing erasers 
Macrodomain-containing proteins are not only capable of binding to 
MARylated proteins, but some of them have been identified also as potent erasers of 
MAR. MACROD1 and MACROD2 have been shown to specifically release MAR 
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from acidic amino acid residues21,33. The structurally related TARG possesses a 
unique catalytic activity with respect to the fact that it does not only release MAR 
from targets comparable to MACROD1 and MACROD2, but also cleaves off entire 
PAR chains by hydrolyzing the ADP-ribose-amino acid-linkage32. Discovery of these 
MAR erasers proved that ADP-ribosylation of acidic amino acids is reversible.  
Macrodomain-containing erasers are mainly localized to the nucleus, with 
MACROD1 also found in the mitochondria and MACROD2 in the cytoplasm. 
Physiologically, MACROD1 and MACROD2 were shown to be mutated or 
differentially expressed in various cancers, pointing towards a tumor suppressor 
function similar to ARH168,69. TARG mutations were shown in individuals with severe 
neurological dysfunctions32.  
 
PARG 
PAR glycohydrolase (PARG) was the first enzyme identified in cell extracts 
of calf thymus to hydrolyze the O-glycosidic bond of PAR chains70,71. PARG is 
inactive towards the ADP-ribose-amino acid linkage, thus leaving a MAR 
modification on target proteins72. The catalytic cleft of PARG was found to share 
homology with macrodomains72.  
Several splice variants of PARG exist, and the respective proteins localize to 
the nucleus, cytoplasm and mitochondria73. The knockout of murine PARG leads to 
embryonic lethality, due to accumulation of PAR, providing evidence that PARG is 
the main responsible protein for PAR degradation in cells and is required during 
embryogenesis74. 
 
1.5 Functional relevance of ADP-ribosylation 
Functions of MAR 
The physiological relevance of MARylation has so far been poorly studied and 
only recently, technological advances allow unraveling the function of specific mono-
ARTDs.  
ARTD3 is an important player in the maintenance of genome integrity. It is 
recruited to DNA double-strand breaks (DSB) and is necessary for mitotic 
progression by stabilizing the mitotic spindle75. Further studies on the role of ARTD3 
in the DNA damage response revealed it to be a key factor in the cell’s choice 
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between homologous recombination (HR) and non-homologous end-joining (NHEJ), 
promoting NHEJ upon DSBs and limiting DSB end resection during HR76. Recent 
evidence implies a role for ARTD3 in single-strand breaks (SSB), where it binds to 
mononucleosomes containing nicked DNA and MARylates the histones77. 
ARTD4, together with the major vault protein (MVP) and telomerase-
associated protein 1 (TEP1), is a component of barrel-shaped cytoplasmic 
ribonucleoprotein particles, so called vaults78. The knockout of ARTD4 in mice leads 
to enhanced susceptibility to carcinogen-induced tumors and germline ARTD4 
mutations were found in cancer patients, indicating a role for ARTD4 in cancer 
development79,80  
ARTD7 (BAL3) along with ARTD8 (BAL2 or CoaSt6) and ARTD9 (BAL1) 
constitute the B-aggressive-lymphoma (BAL) protein family81. The family shares 
some distinct feature in that all members harbor several macrodomains and an ART 
domain81. The function of ARTD7 remains unknown to date.  
ARTD8 is an interaction partner of STAT6, a transcription factor activating 
gene transcription in the IL-4 signaling pathway82,83. Under non-stimulated conditions, 
ARTD8 is found at promoters of STAT6 responsive genes, and bound to HDAC2 and 
3, working as a repressor84. Upon stimulation with Il-4, STAT6 gets phosphorylated, 
dimerizes and shuttles to the nucleus84. In parallel, ARTD8 gets activated in the 
nucleus by a so far unknown mechanism, and ADP-ribosylation of the HDACs and 
ARTD8 leads to their release from chromatin, allowing STAT6 to bind and activate 
transcription84. MARylation is crucial for these events, as treatment with unspecific 
PARPi blocks transcription and a catalytically inactive ARTD8 mutant fails to 
activate STAT6 target genes85. 
ARTD9 has long been thought to be catalytically inactive, as it has never been 
capable of auto-ADP-ribosylation in vitro14. However, a recent publication has shown 
that a heterodimer of ARTD9 and Dtx3L functions in ubiquitin ADP-ribosylation, 
thereby hindering ubiquitination of substrates86.  
ARTD10 was shown to interact with several kinases, and the validation of 
these findings with GSK3β, has shown that in vitro ADP-ribosylation reduced its 
activity87. Knocking down ARTD10 in cells leads to an increase in kinase activity, 
similar to overexpression of the eraser MACROD221. Furthermore, ARTD10 was 
reported to MARylate NEMO, an important protein in the inflammatory NF-κB 
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pathway, which interferes with its poly-ubiquitination and further downstream 
signaling, thereby preventing the transcription of target genes such as IκB and IL-888. 
ARTD11 plays a role in nuclear pore complex organization, as revealed by a 
recently developed mass spectrometry approach89. The technique involves the 
overexpression of an engineered ARTD capable of only metabolizing a clickable 
NAD+ analog, and modified targets can easily get enriched and subjected to mass 
spectrometry measurements89.  
ARTD12 function is not fully understood. Transcriptome analysis revealed it 
to be expressed upon interferon treatment of cells, where it is recruited to stress 
granules to block mRNA translation90. In contrast, lipopolysaccharide (LPS) 
stimulation of cells leads to binding of ARTD12 to proteins of the NF-κB pathway, 
which increases inflammatory signaling90. 
ARTD14 is induced by treatment of cells with 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), a toxin produced as a byproduct in industrial processes91. Upon 
TCDD binding to the aryl hydrocarbon receptor (AHR), the receptor translocates to 
the nucleus where it binds to the AHR nuclear translocator (ARNT), and leads to the 
transcription of various genes, including ARTD1491,92. ARTD14 regulates the 
pathway as a transcriptional repressor93. AHR has been shown to be ADP-ribosylated 
by ARTD14, and MACROD1 reverses this reaction in vitro, such that overexpression 
of MACROD1 in cells leads to the loss of ARTD14-mediated repression of AHR 
signaling94. 
MARylation in the ER by ARTD15 seems to impact the unfolded protein 
response (UPR). Under ER stress, ARTD15 MARylates IRE1α and PERK, and 
thereby increases their kinase activity, leading to enhanced downstream effects such 
as the inhibition of translation and the transcription of chaperones95. 
ARTD16 is a so far completely uncharacterized protein of the ARTD family.  
ARTD17 functions in neuronal development, where it is crucial for 
hippocampal dendrite morphogenesis, and its MARylation activity is needed for the 
development of dendritic complexity in primary hippocampal neurons96. ARTD17 
expression is associated with poor prognosis in various cancers, and its expression 
promotes growth and survival of colorectal adenocarcinoma cells97.  
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Functions of PAR 
Some ARTDs have been shown to catalyze the formation of PAR chains with 
a length of up to 200 ADPr units98. Adding two negative charges per ADPr, this 
drastically changes the electrostatic characteristics of a modified protein, changing its 
structure and function. Additionally, PAR might provide an extensive scaffold for 
recruiting proteins.  
ARTD1 is the most-studied member of the ARTD family and will therefore be 
discussed in more detail. ARTD1 inhibitors (PARP inhibitors (PARPi)), have recently 
been used in the treatment of BRCA-mutated cancers because of the crucial role of 
ARTD1 in the DNA damage control99,100. The three zinc finger (ZF) domains of 
ARTD1 help to bind DNA and to recognize both SSB and DSB and mediate ARTD1 
homodimer formation101,102. ARTD1 has therefore been implicated in SSB repair, 
where it serves as a detector and, through activation and auto-PARylation, recruits 
repair factors such as XRCC1, APE1, DNA ligase 3 and PCNA103. Therefore, 
inhibition of ARTD1 causes replication fork stalling at unrepaired SSBs, which in 
turn causes the formation of DSB104. Tumor cells, which have mutations in the BRCA 
genes, are incapable of repairing DSBs via HR. Hence, treatment of such tumors with 
PARPi leads to genomic instability and eventually tumor cell death105.  
ARTD1 has also important functions in inflammatory responses. ARTD1-
deficient mice are resistant to septic shock induction by LPS-induced septic shock106. 
Similarly, ARTD1-deficiency or treatment with PARPi led to ameliorated or delayed 
symptoms in several inflammatory disease models107. On a molecular level, this is 
thought to be mainly dependent on the function of ARTD1 as a cofactor of NF-
κB108,109.  
Furthermore, ARTD1was shown to be implicated in adipogenesis, as PARPi-
treated mice on a high-fat diet accumulated less white adipose tissue and were lighter 
compared to vehicle-treated mice110. Also, during the in vitro differentiation of 
fibroblasts to adipocytes, PAR is formed, and the inhibition or depletion of ARTD1 
delays adipogenesis, indicating an important role for ADP-ribosylation in the 
differentiation of fat cells111. This effect has been shown to work likely via the 
binding of ARTD1 to the peroxisome proliferator-activated receptor 2 (PPARγ2), a 
key factor in terminal adipocyte differentiation110. ARTD1 binds and PARylates 
PPARγ2, which enhances PPARγ2 binding to ligands, triggers the exchange of co-
  20 
factors at PPARγ2 response elements (PPREs), and leads to PPARγ2-target gene 
expression111. These events coincide with a change in DNA methylation and the 
histone mark landscape, the exact mechanism of which remains unclear110-112.      
One mode of action by which ARTD1 regulates cellular responses is via 
transcriptional regulation. Firstly, similar to its function as a cofactor of NF-κB in 
inflammation, ARTD1 was shown to form complexes with transcription factors in 
processes such as development and differentiation. Oct-1 and Sox2 are only two out 
of many other transcription factors whose activating or repressing function on 
transcription is dependent on ARTD1 binding and activity113,114.  Secondly, ARTD1 
can directly act on chromatin itself, and PARylation was shown to open chromatin 
structure, thereby making the DNA more accessible115.  
 
1.6 Chromatin organization 
DNA packaging 
The genetic information of every cell is packaged within the nucleus in the 
form of chromosomes. The components making up the chromosomes are collectively 
called chromatin, which itself is a complex structure consisting of proteins, DNA and 
RNA molecules. Histones are the main protein component, building up the so called 
nucleosome, which is a histone octamer, each containing two units of H2A, H2B, H3, 
and H4 with 146 base pairs of DNA wrapped around116. Early attempts to visualize 
chromatin showed that DNA wrapped around histones builds up in the form of a 
chain, which served as a base for the so called beads-on-a-string model117.  Higher 
order structures are built with inclusion of H1 in between nucleosomes, wrapping 
another 20 bp of DNA around, which yields a 30 nm wide fiber that upon binding to 
additional scaffold proteins makes up the individual chromosomes118. However, the 
latest developments in electron microscopy revealed that this view might need to be 
changed, as chromatin seems to rather be made up of flexible and disordered chains of 
5-24 nm diameter packed together at different densities119. The packaging of DNA 
into chromatin and chromosomes is required to keep an order and allow for 
segregation of sister chromosomes during cell divisions. However, this high degree of 
packaging poses various challenges during repair, replication, or transcription, where 
DNA needs to be highly accessible for various proteins such as polymerases and 
transcription factors.  
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Euchromatin and heterochromatin 
Cell cycle, cell type and other internal and external cues influence chromatin 
structure. Ways to alter chromatin are the recruitment of remodeling complexes 
capable of loosening or tightening chromatin by displacing nucleosomes or by using 
PTMs such as acetyl-, methyl-, ADP-ribosyl- and phosphogroups to modify 
histones120,121. Simplified, chromatin comes in two flavors, euchromatin and 
heterochromatin, both states marked with different PTMs of histone tails protruding 
from the nucleosome. Open, accessible euchromatin is marked with acetylation of H3 
and H4, and promoters of actively transcribed genes are marked with H3K4me3121. 
Promoters of repressed genes are marked by H3K9me3 and H3K27me3122.  
 
1.7 Chromatin ADP-ribosylation 
Histone ADP-ribosylation 
Besides the commonly known acetylation and methylation of histones, core 
histones as well as H1 were found to be ADP-ribosylated already almost 40 years 
ago19,123,124. ADP-ribosylation is mostly detected on the protruding histone tails. In 
vitro, ARTD1 and ARTD10 modify core histones20,125. ARTD2 did not show activity 
on histones, but the nuclear MAR writer ARTD3 modifies the linker histone H120,126.  
Analysis of histones purified from cells confirmed also in vivo ADP-ribosylation of 
histones26. As described above, several ARTDs and erasers are present in the cell 
nucleus (see Table 1 and 2). However, it is not yet clear which ARTD modifies which 
histone residue in vivo.  
 
Global chromatin ADP-ribosylation 
Different approaches have been undertaken to study the effect of ADP-
ribosylation on overall chromatin structure aside from histones. In vitro PARylation 
of chromatin in the presence of NAD+ and ARTD1 led to a reversible 
decondensation127,128. Further studies have shown ADP-ribosylated chromatin to be 
more susceptible to micrococcal nuclease digest129. In vivo, studies on the Hsp70 locus 
in Drosophila melanogaster support the aforementioned findings as ARTD1 activity 
has been shown to loosen up chromatin to ensure gene transcription115.  
Global chromatin ADP-ribosylation in vivo has been analyzed so far using two 
different approaches. In the first protocol, a PAR antibody was used to perform ChIP 
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upon crosslinking and TCA precipitation130. A recently developed ChAP protocol 
describes the enrichment of PARylated chromatin using the WWE domain of 
RNF146 and the subsequent sequencing of associated DNA36,131. It will be interesting 
to see how these techniques develop and whether the establishment of specific 
protocols addressing MARylated chromatin will help understand better the roles of 
ADP-ribosylation.   
 
DNA ADP-ribosylation 
In addition to direct chromatin modification or interference with chromatin 
remodelers and transcription factors, ARTDs have been implicated in DNA ADP-
ribosylation. Pierisin, a protein found in a cabbage butterfly (Pieris rapae), modifies 
guanines, which is cytotoxic132. Whether mammalian DNA is naturally ADP-
ribosylated or not remains to be elucidated.  
Together, all these findings support a view where ADP-ribosylation and 
removal thereof might greatly influence accessibility, structure and function of 
chromatin at different loci (Figure 3).  
 
Figure 3: ARTDs in chromatin regulation. ARTDs could influence chromatin on 
different levels. a) Direct interaction of an ARTD with promoters in order to stimulate or 
repress transcription; b) ARTDs as cofactors of transcription factors (TF); c) ADP-
ribosylation of chromatin might work either as scaffold or might sterically hinder access 
of chromatin remodeling proteins and complexes (CM); d) ADP-ribosylation of histones 
might either coincide or be mutually exclusive with other histone marks; e) emerging as 
a new DNA PTM as well, ADP-ribosylation might serve as an additional level of 
regulation of DNA stability and accessibility. Modified from133. 
 
 
="ADP&ribosyla/on"
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2 Aim of the thesis 
Since the discovery of ADP-ribosylation as a PTM, most research was focused 
on ARTD1-mediated PARylation and its functions. Recently, several studies started 
investigating the role of mono-ARTDs and the pathways they are regulating, and thus 
revealing that also MARylation is an important regulatory PTM in cells. The 
identification of MACROD1, MACROD2 and TARG as erasers for MARylated 
acidic amino acid residues (i.e. D/E) as well as of ARH1 as eraser for MARylated R’s 
provided strong evidence that ADP-ribosylation is a fully reversible PTM, also 
implying that erasers for S and K MARylation may exist as well (Figure 4).  
 
 
The aim of this thesis was to identify the enzyme(s) able to hydrolyze the 
linkage of ADP-ribose attached to K and S. Moreover, the enzyme should be further 
characterized in its physiological context, including the identification of its targets and 
the investigation of its role in the cellular and organismal context.  
 
PARG 
ARH3 
De-PARylation 
 
MACROD2 (E/D) 
MACROD1 (E/D) 
C6ORF130 (E/D) 
ARH1 (R) 
(K) 
(S) 
 
Mono-ADP-ribosylation 
Poly-ADP-
ribosylation 
??? 
e.g. ARTD10 
e.g. ARTD1, 
ARTD2 
De-MARylation 
="ADP&ribosyla/on"
K/R"
D/E"
S"
Figure 4: The ADP-ribosylation cycle. ADP-ribosylation of D/E and R is reversible. No known 
hydrolases for the removal of K and S ADP-ribosylation have been identified yet.  
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3 Results 
3.1 Overview of published manuscripts 
Cell fate regulation by chromatin ADP-ribosylation 
Authors:  Jeannette Abplanalp and Michael O. Hottiger 
Journal:  Seminars in Cell & Developmental Biology, 2017; 63, p. 114-122 
Contribution J.A.:  Writing and drafting of the manuscript and figures. 
 
New Quantitative Mass Spectrometry Approaches Reveal Different ADP-
ribosylation Phases Dependent On the Levels of Oxidative Stress 
Authors:  Vera Bilan, Nathalie Selevsek, Hans A.V. Kistemaker, Jeannette 
Abplanalp, Roxane Feurer, Dmitri V. Filippov and Michael O. 
Hottiger  
Journal: Mol Cell Proteomics, 2017; 5, p.949-958 
Contribution J.A.: Performing Western blot analysis of oxidative stress markers in 
lysates of H2O2-treated HeLa cells (Suppl. Figure 3A). 
 
3.2 Overview of submitted manuscripts 
Proteomic analyses identify ARH3 as a serine mono-ADP-ribosylhydrolase 
Authors:  Jeannette Abplanalp, Mario Leutert, Emilie Frugier, Roxane 
Feurer, Jiro Kato, Joel Moss, Amedeo Caflisch and Michael O. 
Hottiger 
Journal:  Manuscript submitted 
Contribution J.A.: Planning, performing and evaluating of most experiments. Writing 
of the manuscript.  
 
Mono-ADP-ribosylhydrolase assays 
Authors:  Jeannette Abplanalp*, Ann-Katrin Hopp* and Michael O. 
Hottiger, * equal contribution 
Journal: Manuscript submitted 
Contribution J.A.:  Writing and drafting of the manuscript and figures.  
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3.3 Unpublished results 
ARH3 is dispensable for the embryonic development in mice 
Nothing is so far known about the physiological role of ARH3 is unknown and 
characterization of the ARH3 knockout (KO) mouse is still missing. We purchased 
mice with a CRISPR/Cas9-mediated exon deletion in the Adprhl2 gene (encoding for 
ARH3) from Genome Research Limited, Wellcome Trust Sanger Institute 
(Cambridge, UK) and characterized them in more detail. Since the obtained mice 
were heterozygous (HET), we tested whether the full KO mice would be viable. Mice 
were bred and all pups from these breedings continuously genotyped. All genotypes, 
including KO mice, of these breeds were viable. In male mice, 56% more wildtype 
(WT) than ARH3 KO pups were born (Figure 5A), but equal numbers of WT and 
ARH3 KO females were born (Figure 5B). Considering all mice, the inheritance of the 
ARH3 WT and KO allele approximately followed the expected Mendelian ratio 
(Figure 5C).  
 
 
 
 
To investigate whether ARH3 KO mice are fertile, homozygous breeding pairs 
were set up and the number and sex of the born pups monitored. No differences in 
litter sizes or altered ratio of females to males was observed comparing WT and 
ARH3 KO breeding pairs (data not shown), suggesting that ARH3 is dispensable for 
embryonic development, for overall survival and fertility of the mice.  
Figure 5: Genotyping analysis of pups from heterozygous breeding pairs reveals 
inheritance of the WT and ARH3 KO allele according to Mendelian ratios. DNA 
of all pups from HET breeding pairs was genotyped and the number of WT, ARH3 
KO and HET A) males, B) females, and C) all mice used to calculate the %. 
A B
 Genotype 
Number of 
animals % 
WT 7 43 
HET 6 38 
KO 3 19 
total 16 100 
 Genotype 
Number of 
animals % 
WT 4 19 
HET 13 62 
KO 4 19 
total 21 100 
 
Genotype Number of animals % Expected % 
WT 11 30 25 
HET 19 51 50 
KO 7 19 25 
total 16 100 100 
Males Females
C Males and females
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ARH3 KO mice show a weight gain during development 
To further characterize the phenotype of ARH3 KO mice, full necropsies of 6-
week-old female mice (n = 3 each genotype) were carried out by Giovanni Pellegrini 
(Laboratory for Animal Model Pathology (LAMP), University of Zurich). No 
histopathological abnormalities were observed in the ARH3 KO mice (data not 
shown). The brains as well as other organs were weighed. The brains weighed 0.425 ± 
0.009 g for WT and 0.440 ± 0.005 g for ARH3 KO mice, respectively (Figure 6A). 
 
 
 
 
 
 
Heart, kidney, liver and spleen were also weighed and the results normalized 
to the brain weight (Figure 6B-6E). No significant differences were observed, 
suggesting that ARH3 is indeed not essential for early mouse development or 
functionally compensated by another ARH. 
During handling and organ isolation of older mice, we discovered that ARH3 
KO animals were bigger and heavier than the WT counterparts, and accumulated 
Figure 6: Organ weights of female 6-week-old ARH3 WT and KO mice are comparable. A) 
Brain weight in grams of each n = 3 WT and ARH3 KO mice. Ratio of the B) heart, C) kidney, 
D) liver, and E) spleen weights divided by the brain weight. Mean ± SEM, ns = not significant, 
two-tailed Student's t-test. 
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more white adipose tissue upon aging. To quantify this difference, we weighed mice 
at two different time points, i.e. 8 and 16 weeks of age, in order to observe a potential 
effect of aging. Male mice at both 8 and 16 weeks of age showed a tendency to be 
heavier (8 weeks: WT = 23.20 ± 0.37 g and ARH3 KO = 24.60 ± 0.81; 16 weeks: WT 
= 29.17 ± 0.67 g and ARH3 KO = 35.33 ± 2.31 g), however, this difference was not 
statistically significant, potentially due to the low number of analyzed animals (Figure 
7A and 7B). Interestingly, ARH3 KO female mice (only measured after 16 weeks) 
were significantly heavier than WT mice (WT = 23.83 ± 0.63 g and ARH3 KO = 
32.12 ± 1.92 g, respectively (Figure 7C).  
 
 
 
 
To investigate whether this gain in total weight is caused by organ weights, we 
isolated organs from 3 female 16-week-old mice of each genotype. When weighing 
the heart, kidney and spleen, we observed that the organs, similar to the body weight, 
Figure 7: Different aged ARH3 KO mice are heavier than age-matched WT 
mice. Body weight in g of A) 8-week-old males (n = 5), B) 16-week-old males (n = 
3 WT and 4 ARH3 KO and C) 16-week-old females (n = 8 WT and 9 ARH3 KO). 
Absolute weights of D) heart, E) kidney and F) spleen. Relative G) heart, H) kidney, 
and I) spleen weights normalized over body weight. (n = 3, one WT heart was not 
weighed by mistake). Mean ± SEM, ns = not significant, p = p-value, two-tailed 
Student's t-test.  
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were heavier in ARH3 KO mice compared to WT (Figure 7D-7F). However, when 
normalizing the organ weight to the total body weight, the organs of ARH3 KO 
animals were rather lighter when compared to WT (Figure 7G-7I), suggesting that 
ARH3 KO animals mainly gained weight due to obesity (i.e. increase in white adipose 
tissue). Although ARH3 KO mice initially showed no obvious phenotype, we 
conclude that ARH3 plays an important metabolic role in aging mice and the 
deficiency of ARH3 leads to a gain in body weight and potentially fat content.  
 
Spleens from ARH3 KO mice show enhanced MARylation 
In this thesis, as well as reported by others during the course of this thesis, we 
described ARH3 as a mono-ARH capable of fully reversing serine-ADP-ribosylation 
(Abplanalp et al., submitted manuscript, and 134). We observed that ARH3 KO mouse 
embryonic fibroblasts (MEF) expressed an enhanced basal, i.e. untreated, ADP-
ribosylome as measured by mass spectrometry. 
To confirm this finding in tissue, we isolated kidneys, livers, hearts, lymph 
nodes, and spleens from 6-week-old male WT, ARH3 KO, or HET mice, and lysed the 
tissue in ice-cold RIPA using a Tissue Lyser II. KO of ARH3 was confirmed by 
Western blot using an antibody against ARH3. MARylation was analyzed with a 
MAR antibody raised against a chemically MARylated H2B peptide and tubulin 
served as loading control (Figure 8, next page). ARH3 was not detected in the kidney, 
liver and heart (Figure 8A-8C). In lymph nodes and the spleen, a distinct band at 39 
kDa representing ARH3 was detected only in the WT and to a lower extent in the 
HET, and completely absent in the tissues of ARH3 KO (Figure 8D and 8E). Specific 
bands marking MARylated proteins were identified in the kidney and the liver (Figure 
8A and 8B). Heart lysates showed extensive MARylation levels (Figure 8C), 
presumably due to the activity of the highly abundant ADP-ribosyltransferase ARTC1 
(see chapter 1.1.1). In lymph nodes we did not detect any MARylation under the 
tested conditions (Figure 8D) but in the spleen various MARylated proteins in the 
lysates of ARH3 KO and HET animals were detected, with some defined bands 
around 75 kDa (Figure 8E). We conclude that while ARH3 was not detectable in the 
kidney, liver, spleen and hearts of 6-week-old mice, ARH3 was present in the lymph 
nodes and the spleen, suggesting a functional role of ARH3 in these two organs. 
Considering MARylation, the kidney and liver showed some specific bands not 
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dependent on ARH3, and enhanced MARylation upon ARH3 KO was only observed 
in the spleen.  
To confirm that MARylation is indeed enhanced in ARH3 KO spleens, we 
additionally isolated organs from 16-week-old female mice (n = 3 WT and ARH3 KO, 
each) and repeated the same Western blot analysis as above. Overall, spleen lysates 
showed enhanced MARylation signals compared to the younger mouse spleens, and 
ARH3 KO mice showed two additional MARylated bands with molecular weights of 
15 and 100 kDa (Figure 8F). Together, the absence of ARH3 caused enhanced 
MARylation in spleen tissue of both 6-week and 16-week-old mice and as mice 
develop, MARylation accumulated in the spleen, indicating that ARH3 seems to 
Figure 8: Spleen lysates of ARH3 KO mice show enhanced basal MARylation 
compared to other tissues. 200 μg of A) kidney, B) liver, C) heart, D) lymph 
node or E) spleen of 6-week-old male mice or 200 μg of F) spleen of 16-week-old 
female mice were blotted against MAR, ARH3 (marked with an arrow), and 
tubulin. WT = wildtype, KO = knockout, HET = heterozygous. 
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become even more important over time as the enzyme responsible for keeping the 
basal ADP-ribosylation in the spleen low. 
 
ARH3 reduces the basal spleen ADP-ribosylome 
Since the ARH3 KO showed various MARylated proteins in contrast to WT 
spleens already at 6 weeks of age (Figure 8E), we aimed to investigate and 
characterize the ADP-ribosylome in this tissue. The spleens of two WT and KO 
animals were isolated and lysed as described section 3.4. Tissue lysates were digested 
with trypsin, treated with PARG and enriched with Af1521 before measured by 
shotgun mass spectrometry. The spectra were generated using a combination of two 
different fragmentation techniques, higher-energy collision dissociation (HCD) and 
electron-transfer/higher-energy collision dissociation fragmentation (EThCD)25. 
Compared to data obtained using ARH3 KO MEFs (Abplanalp et al., submitted 
manuscript), where searches included five different possible ADP-ribose acceptor 
sites (i.e. D, E, K, R and S), we here included also Y, since recent efforts from our 
laboratory provide evidence that Y can also serve as an ADP-ribose acceptor site 
(data not shown). We filtered the data with a localization score > 95%, to only obtain 
ADP-ribose acceptor sites with very high confidence. Spleens from ARH3 KO mice 
compared to WT mice showed an overall 3-fold increased number of spectra with 
ADP-ribosylated peptides (peptide-spectrum matches (PSMs) (Figure 9A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: ARH3 KO spleens show an extensive serine ADP-ribosylome. 10 mg 
of spleen lysate of 6-week-old mice was digested with trypsin and the ADP-
ribosylome enriched before subjecting the samples for mass spectrometric 
analysis. A) Peptide-sprectrum matches (PSMs) in WT and ARH3 KO spleens. B) 
Total ADP-ribosylated proteins. C) Numbers of identified HCD spectra per amino 
acid. D) Numbers of identified EThCD spectra per amino acid. For C) and D), a 
modification confidence threshold of > 95% was set.  
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The same trend was observed when analyzing the data at the protein level, where 
ARH3 KO spleens showed a 2.5-fold higher number of ADP-ribosylated targets 
(Figure 9B). Both HCD and EThCD spectra (Figure 9C and 9D, respectively) 
revealed that serine is the main ADP-ribose acceptor site in the spleen of ARH3 KO 
mice. Taken together, spleens from ARH3 KO animals harbor an extensive basal 
ADP-ribosylome, even under unstimulated conditions. We therefore hypothesize that 
ARH3 is constitutively active in unstressed cells and de-ADP-ribosylates its targets 
under basal conditions, maintaining a low amount of ADP-ribosylation. 
 
ARH3 mainly demodifies nuclear proteins  
Based on the observation that the absence of ARH3 lead to an enhanced ADP-
ribosylome, the acquired MS data set was further analyzed. By plotting the proteins 
into a Venn diagram, a very high overlap between the duplicates was observed (2 
spleens from WT and 2 spleens from ARH3 KO mice), with 18 common proteins 
between the two WT samples (37%) and 68 common proteins between both ARH3 
KO samples (around 57% overlap) (Figure 10A and 10B, next page).  
A total of 17 proteins were modified in all analyzed samples (common to WT 
and ARH3 KO), representing the basal ARH3-independent spleen ADP-ribosylome 
(Figure 10C). For the histone variants H2ax, H1.4, and H2b type 1-b, we observed a 
considerably higher amount of PSMs measured in the ARH3 KO spleens compared to 
WT spleens (Figure 10D), suggesting that they are likely ARH3 target proteins. 
Another highly modified protein found mainly in the spleen of ARH3 KO mice was 
ARTD1 (PARP1), suggesting that ARH3 regulates the ADP-ribosylation state also of 
ARTD1 and possibly its enzymatic activity. Since the analysis was not quantitative, 
the level of ARH3 dependency requires additional experiments. Another group of 40 
proteins was however exclusively ADP-ribosylated in the ARH3 KO spleens, and 
therefore considered to be confirmed targets of ARH3 (Figure 10E). Chromobox 
protein homolog 5 (Cbx5), lamin-B receptor (Lbr), lamin A/C (Lmna) and 
nucleophosmin (Npm1) were quite extensively modified in the absence of ARH3. The 
molecular mass of Lbr and Lmna are 71 kDa and 74 kDa, respectively, which might 
potentially correspond to the prominent bands detected on the Western blot using the 
MAR antibody (Figure 8E). 
  86 
   Figure 10: The basal spleen ADP-ribosylome consists of histones mainly and deficiency of ARH3 leads to 
an enhanced ADP-ribosylome of proteins involved in nuclear export and DNA packaging. Venn diagram 
of ADP-ribosylated proteins identified in A) both WT and B) both ARH3 KO spleens. C) Venn diagram of all 
four measured spleen samples. D) List of the 17 proteins detected in all spleen samples and their corresponding 
PSM counts. E) List of the 40 proteins found exclusively in the spleens of KO mice and their number of 
identified PSMs. Genome ontology terms for F) molecular function, G) cellular component, and H) biological 
function. 
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ARH3 
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Gale UDP-glucose 4-epimerase 1 2 3 1 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 1 1 1 1 
Gm28062 Heterogeneous nuclear ribonucleoprotein U 5 1 8 10 
H2afx Histone H2AX 2 2 20 23 
H3f3c Histone H3.3C 1 1 1 4 
Hba-a1 Hemoglobin subunit alpha 10 9 3 8 
Hbbt1 Beta-globin 7 7 3 3 
Hist1h1e Histone H1.4 1 2 22 25 
Hist1h2bb Histone H2B type 1-B 2 3 8 11 
Hist1h2bf Histone H2B type 1-F/J/L 4 10 7 19 
Hist1h2bm Histone H2B type 1-M 3 4 6 6 
Hist2h2bb Histone H2B type 2-B 2 3 6 7 
Hist2h3b Histone H3.2 5 11 15 18 
Hist3h2bb Histone H2B type 3-B 1 1 1 1 
Hnrnpa1 Heterogeneous nuclear ribonucleoprotein A1 1 1 2 3 
Parp1 Poly [ADP-ribose] polymerase 1 6 2 23 26 
Parp14 Poly [ADP-ribose] polymerase 14 1 3 2 1 
 
Gene 
name Protein name 
ARH3 
KO 1 
ARH3 
KO 2 Gene name Protein name 
ARH3 
KO 1 
ARH3 
KO 2 
N/A Uncharacterized protein C1orf131 homolog 2 2 Kifc5b Kinesin-like protein KIFC1 1 1 
N/A Uncharacterized protein C11orf98 homolog 1 3 Lbr Lamin-B receptor 8 9 
C1qb Complement C1q subcomponent subunit B 2 1 Limd2 LIM domain-containing protein 2 2 2 
Cbx3 Chromobox protein homolog 3 1 2 Lmna Prelamin-A/C 3 7 
Cbx5 Chromobox protein homolog 5 8 7 Mecp2 Methyl-CpG-binding protein 2 4 2 
Cenpv Centromere protein V 1 1 Mybbp1a Myb-binding protein 1A 3 3 
Chd1l Chromodomain-helicase-DNA-binding protein 1-like 1 1 Npm1 Nucleophosmin 5 9 
Cherp Calcium homeostasis endoplasmic reticulum protein 1 2 Pola1 DNA polymerase alpha catalytic subunit 1 1 
D8Ertd738e Leydig cell tumor 10 kDa protein homolog 1 2 Rfc1 Replication factor C subunit 1 2 3 
Ddx21 Nucleolar RNA helicase 2 2 1 Sarnp SAP domain-containing ribonucleoprotein 1 3 
Edf1 Endothelial differentiation-related factor 1 3 4 Senp3 Sentrin-specific protease 3 1 1 
Gm16494 Predicted gene 16494 2 2 Ssb Lupus La protein homolog 2 2 
Gtf3c2 General transcription factor 3C polypeptide 2 1 1 Tcof1 Treacle protein 4 5 
H1f0 Histone H1.0 2 2 Thumpd1 THUMP domain-containing protein 1 2 3 
Heatr1 Heatr1 protein 1 1 Top2a DNA topoisomerase 2-alpha 3 6 
Hist1h1c Histone H1.2 4 4 Trip12 E3 ubiquitin-protein ligase TRIP12 1 2 
Hmga1 High mobility group protein HMG-I/HMG-Y 3 5 Wiz Protein Wiz 2 2 
Hmgb3 High mobility group protein B3 3 2 Yy1 Transcriptional repressor protein YY1 1 2 
Hnrnpa2b1 Heterogeneous nuclear ribonucleoproteins A2/B1 1 1 Zfp800 Zinc finger protein 800 1 4 
Ifi204 Interferon-activable protein 204 4 5 Znf22 Zinc finger protein 22 3 2 
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Next, a gene ontology (GO) analysis for the molecular function including the 
40 proteins exclusively modified in ARH3 KO spleens compared to the entire mouse 
proteome was performed and revealed enriched terms in DNA- and RNA-binding 
proteins (Figure 10F). The cellular component analysis revealed highly significant 
enrichments for proteins of the nuclear periphery and the nucleolus, and both eu- and 
heterochromatin (Figure 10G). We also analyzed the GO terms for biological 
function, which revealed an enrichment in ribonucleoprotein complex export, nuclear 
export as well as DNA packaging, DNA-damage response proteins and proteins 
involved in transcription (Figure 10H).  
Together, this data hints at ARH3 being responsible for the basal de-ADP-
ribosylation of mainly nuclear, chromatin-associated and regulating proteins, 
suggesting that ARH3 functions in the regulation of heterochromatin assembly to the 
nuclear lamina and regulates the ADP-ribosylation state of proteins involved in 
general nuclear export, and potentially also of ribosome export. Additionally, the 
increase in ADP-ribosylated proteins of the DNA damage response in absence of 
ARH3 suggests a role of ARH3 as regulator of stress-induced ARTD1 ADP-
ribosylation. 
 
The total level of H3 lysine 27 trimethylation is reduced in ARH3 KO MEFs  
Considering the high number of ADP-ribosylation sites of core histones and linker 
histone 1 in ARH3 KO MEFs (Abplanalp et al., manuscript submitted, and previous 
subchapter), we hypothesized that increased histone ADP-ribosylation might interfere 
with other known histone marks in this context. Since recombinant ARH3 is a potent 
hydrolase of ARTD1-modified H3-tail, we focused on other known H3 modifications. 
We prepared whole cell lysates of WT and ARH3 KO MEFs and performed Western 
blots detecting H3 (Figure 11A, next page), acetylated H3 (Figure 11B), and H3 
specifically dimethylated at position K9 (Figure 11C) or trimethylated at K27 (Figure 
11D). While global levels of total H3, acetylated H3 as well as H3K9me2 were not 
altered, we observed a decrease in the repressive histone mark H3K27me3 in ARH3 
KO MEFs compared to WT cells, suggesting that ARH3 is required for either the 
establishment or the maintenance of H3K27me3 in the context of MEF cells. 
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ARH3 binds nuclear proteins 
Besides finding potential targets of ARH3 that are demodified, we were also 
interested in identifying other binding partners that might regulate ARH3 (e.g. 
cofactors). As no commercially available antibody for direct immunoprecipitation of 
ARH3 was available, we generated a FLAG-tagged version of ARH3, which can be 
easily enriched and further analyzed using FLAG-beads. To confirm that an N-
terminal tag would not interfere with physiological localization of ARH3, we 
overexpressed GFP-, HA-, and FLAG-tagged ARH3 in 3T3 mouse fibroblast cells 
(Figure 12 A-C, next page). All constructs localized to the nucleus, which is in line 
with our previous results (Abplanalp et al., submitted manuscript), confirming that an 
N-terminal tag does not interfere with the physiological nuclear localization of ARH3.  
To identify potential binding partners of ARH3, we next overexpressed an 
empty vector (EV) or a vector containing FLAG-ARH in 3T3 cells. Cells were lyzed 
and the lysates incubated with FLAG-beads. After several washing steps, a FLAG-
peptide was used to elute the proteins that bound to the FLAG-beads. Silver staining 
of an SDS-PAGE gel of the eluates revealed that FLAG-ARH3 was successfully 
pulled down and eluted (Figure 12D, band at 40 kDa). Mass spectrometric analysis of 
the eluates allowed identifying proteins that only bound to FLAG-tagged ARH3 
Figure 11: ARH3 promotes the repressive histone mark H3K27me3. 
Western blot analysis of 50 ug whole cell lysate of WT and ARH3 KO MEF 
cells. A) H3, B) Acetyl-H3, C) H3K9me2, and D) H3K27me3. Representative 
images out of three independent experiments are shown.  
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(Figure 12E). The most prominently identified proteins were nuclear proteins, e.g. 
heterogeneous nuclear ribonucleoprotein K (Hnrnpk), Ras GTPase-activating protein-
binding protein 1 (G3bp1) and Exportin-2 (Xpo2). Interestingly, these proteins were 
not found to be modified in our MS analysis and will need further validation, but still 
suggest that ARH3 is localized to the nucleus and plays a role in DNA- and RNA-
associated processes or might be regulated by these proteins.  
 
 
 
ARH3 represses iNos expression, yet enhances its activity upon LPS stimulation 
Considering the function of ARH3 as a mono- and poly-ADP-ribosylhydrolase 
that demodifies many chromatin components (i.e. histones), and knowing that both 
MARylation and PARylation play important roles in inflammatory responses (see 
2.1.4), we investigated a potential regulatory role of ARH3 in LPS-induced 
inflammation. LPS-treatment of cells and binding of LPS to the toll-like receptor 4 
(TLR4) induces a well understood signaling cascade as part of the specific innate 
immune response135. Intracellularly, this signaling leads to the phosphorylation of 
Figure 12: FLAG-ARH3 localizes to the nucleus and binds to nuclear proteins. A) 
Immunofluorescence pictures of 3T3 cells transfected with A) GFP-, B) HA-, or C) FLAG-
tagged ARH3. D) Silverstaining of proteins eluted from FLAG-beads upon binding of cell 
lysates from empty vector (EV) or FLAG-ARH3-transfected 3T3 cells. E) List of potential 
ARH3 binding proteins.  
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Hnrpk Heterogeneous nuclear ribonucleoprotein K 11 
G3bp1 Ras GTPase-activating protein-binding protein 1 10 
Xpo2/Cse1l Exportin 2 6 
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Ecm29 Proteasome-associated protein ECM29 homolog 4 
Rhox5 Homeobox protein Rhox5 3 
Bzw2 Basic leucine zipper and W2 domain-containing protein 2 3 
Marcks Myristoylated alanine-rich C-kinase substrate 3 
Gsdma Gasdermin-A3 3 
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IκB, which is thereafter ubiquitinated and degraded, exposing the nuclear localization 
signal of NF-κB a heterodimeric interaction partner of IκB. This subsequently leads 
to the translocalization of NF-κB to the nucleus, where it activates the expression of 
different genes including those of cytokines. This transcriptional activity can easily be 
monitored by qPCR. To investigate a potential involvement of ARH3 in LPS-induced 
cytokine signaling, we first assessed whether transcription of ARH3 itself is regulated 
upon LPS-induced NF-κB activation. We isolated cells from the bone marrow of WT 
mice and differentiated them to bone marrow-derived macrophages (BMDM). The 
cells were treated with LPS for 1h, 4h, 8h, 12h, or 24h, respectively, RNA was 
isolated, reverse transcribed and the cDNA analyzed by qPCR (cDNA kindly 
provided by Friedrich Kunze). Interestingly, while the mRNA levels of the 
housekeeping gene RPS12 were relatively stable over the course of the treatment 
(Figure 13A, next page), ARH3 mRNA was upregulated 10-fold after 8h and 12h of 
LPS treatment (Figure 13B), suggesting ARH3 expression itself is regulated by the 
LPS-signaling.  
To investigate how ARH3 might influence the inflammatory response, we 
knocked down ARH3 in 3T3 cells by siRNA and assessed the expression of NF-κB-
target genes such as IL6, IP10, and iNos after 4h of LPS treatment. Levels of the 
housekeeping gene RPS12 were comparable for siMock- and siARH3-treated 3T3 
cells, suggesting that ARH3 deficiency does not affect cell viability (Figure 13C). The 
expression levels of ARH3 were reduced to 65% when applying siARH3, indicating 
that the siRNA treatment worked (Figure 13D). The expression of the inflammatory 
genes IL6 (Figure 13E) and IP10 (Figure 13F) were both induced upon LPS 
treatment, however remained unchanged in siMock to siARH3 cells. However, the 
inflammatory gene iNOS was upregulated upon ARH3 knockdown and LPS 
treatment, suggesting a regulatory role of ARH3 in its expression (Figure 13G).  
 To confirm this finding in another cell line, we repeated the experiments with 
RAW macrophages. As this cell type is not easily transfectable with siRNA, we 
transduced cells with shMock and shARH3 retroviral constructs. Similar to the siRNA 
treatment, shMock and shARH3 did not affect the expression of the housekeeping 
gene RPS12 (Figure 13H). ARH3 levels were again downregulated to approximately 
one third comparing shARH3 to shMock RAW cells (Figure 13I). As observed before 
for 3T3 cells, iNOS expression was upregulated upon LPS treatment in shARH3 cells  
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Figure 13: ARH3 regulates the transcription and activity of iNOS upon LPS stimulation of 3T3 
and RAW cells.  Bone marrow-derived macrophages were isolated and stimulated with 10 ng/ml LPS 
for the indicated time points and mRNA levels of A) RPS12 and B) ARH3 measured. 3T3 cells were 
treated with siMock or siARH3 for 48-72h and treated with 100 ng/ml LPS. C) RPS12, D) ARH3, E) 
IL6, F) IP10, and G) iNOS mRNA levels were assessed. n = 6 for C), D), and G) and n = 3 for E) and 
F). Mean ± SEM, ns = not significant, p = p-value, two-tailed Student's t-test. RAW cells stably 
expressing an shMock or shARH3 construct were treated with 100 ng/ml LPS for 4h and expression of  
H) RPS12, I) ARH3, and J) iNOS measured by qPCR. K) Western blot of iNOS protein levels upon 24h 
and 48h of 10 ng/ml LPS treatment of shMock and shARH3 RAW cells. n = 2, no statistical analysis 
performed. L) Griess assay measuring iNOS catalytic activity of these cells. n = 4, mean ± SEM, p = p-
value, two-tailed Student's t-test. M) Bright-field microscopy (10x) pictures of shMock and shARH3 
RAW cells 24h and 48h treated with LPS. 
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compared to shMock (Figure 13J), suggesting that ARH3 dampens the expression of 
iNOS in 3T3 and RAW cells. 
 In addition, we assessed the protein levels of iNOS in shMock and shARH3 
cells upon 24h and 48h treatments with LPS. After 24h, iNOS was equally expressed 
in both shMock and shARH3 RAW cells (Figure 13K), suggestion that the observed 
transcription differences did not affect the translation efficiency of iNOS. Next, we 
characterized also the iNOS catalytic activity using the Griess assay. Surprisingly, a 
significant drop in iNOS activity was observed in shARH3 cells both after 24h and 
48h of LPS treatment (Figure 13L), suggesting that ARH3 directly or indirectly 
regulates iNOS activity, potentially by binding or via modulating its ADP-
ribosylation state. Due to the mainly cytoplasmic localization of iNOS, we assume a 
rather indirect effect of ARH3 on iNOS. Moreover, we also observed an interesting 
morphological change in shARH3 RAW cells upon treatment with LPS, which might 
indicate more drastic expression changes arising through the knockdown of ARH3 
(Figure 13M).  
 Together, all this data suggests an inhibitory role of ARH3 for the expression 
of iNOS upon LPS stimulation in 3T3 and RAW cells, and a direct or indirect 
stimulating role on iNOS catalytic activity.  
 
ARH3 differentially regulates iNOS expression upon LPS-stimulation in various 
cell types 
To assess ARH3 function in inflammation at a more physiological level, we 
directly characterized the LPS response of BMDMs from WT and ARH3 KO mice. 8-
week-old males (n = 5 each genotype) were sacrificed and their bone marrow pooled. 
After differentiation, the macrophages were treated with LPS for 4h and their RPS12, 
ARH3, and iNOS mRNA expression levels measured using qPCR. RPS12 levels were 
comparable between WT and ARH3 KO macrophages (Figure 14A, next page) and as 
expected, ARH3 levels were undetectable in the ARH3 KO cells (Figure 14B). 
Interestingly, compared to the results from siARH3 3T3 and shARH3 RAW cells, 
macrophages isolated from ARH3 KO animals did not show an altered iNOS 
transcription (Figure 14C).  
We also used the BMDMs for a Griess assay to monitor iNOS activity. Here, 
similar to the shRAW cells, the enzymatic activity of iNOS from ARH3 KO mouse 
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cells was undetectable 24h after the addition of LPS, while iNOS activity was easily 
observed in the WT cells (Figure 14D), suggesting that ARH3 indeed regulates the 
iNOS activity even in this context. 
 
 
Figure 14: iNOS upregulation is differently regulated by ARH3 depending on the cell type. 
BMDMs from ARH3 WT and KO mice were isolated and treated with 10 ng/ml LPS for 4h and A) 
RPS12, B) ARH3, and C) iNOS levels assessed by qPCR. D) Griess assay of BMDM after 24 h of 10 
ng/ml LPS stimulation. Mouse ear fibroblasts from wt and ARH3 ko mice were treated with 100 ng/ml 
LPS for 4 h and E) RPS12, F) ARH3, and G) iNOS levels quantified by qPCR. MLFs from ARH3 WT 
and KO mice were treated with 100 ng/ml LPS for 4 h and H) RPS12, I) ARH3, and J) iNOS levels 
assessed by qPCR. MEFs were treated with 100 ng/ml LPS for 4 h and K) RPS12, L) ARH3, and M) 
iNOS levels assessed by qPCR. 
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Additionally to the macrophages, we also isolated fibroblasts of the ear, lung 
and skin. Ears or lungs of two animals from each genotype were pooled and cultured 
for several passages, then treated with LPS for 4h. Similar to 3T3 cells, ear fibroblasts 
showed comparable RPS12 levels (Figure 14E), and ARH3 was undetectable in the 
ARH3 KO cells (Figure 14F). iNOS was upregulated upon LPS stimulation and its 
expression further increased in the ARH3 KO cells (Figure 14G). However, for the 
mouse lung fibroblasts (MLF), the results looked surprisingly different. While the 
RPS12 levels were fairly equal (Figure 14H), the MLF ARH3 KO cells expressed 
basal levels of ARH3 (Figure 14I) and showed a decrease in iNOS expression upon 4h 
LPS treatment (Figure 14J). In MEFs (provided by Joel Moss), RPS12 levels were 
comparable (Figure 14K), and the ARH3 KO cells also showed detectable levels of 
ARH3 (Figure 14L). Comparable to MLFs, the MEF cells showed a decrease of iNOS 
expression upon LPS stimulation in the ARH3 KO compared to the WT (Figure 14M). 
Taken together, although the effect of ARH3 on iNOS activity was reproducible, the 
transcription analysis involving different cell types were inconclusive and did not 
allow an assessment of the function of ARH3 in this regard. 
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3.4 Methods to unpublished results 
Animals 
Breeding pairs for the ARH3 KO mouse strain C57BL/6N-
Adprhl2<em2Wtsi>/Wtsi were purchased from Genome Research Limited, Wellcome 
Trust Sanger Institute (Cambridge, UK). All mice were bred at the animal facility of 
the University of Zurich and maintained on a 12-h light–dark cycle with regular 
unrestricted diet. All animal experiments were carried out in accordance with the 
Swiss and EU ethical guidelines and have been approved by the local animal 
experimentation committee of the Canton of Zurich under license #ZH207/15 and 
following the 3R guidelines. Giovanni Pellegrini from the laboratory for animal 
model pathology, University of Zurich, carried out necropsies and histopathological 
phenotyping. 
 
Mouse genotyping 
DNA isolation. Toe biopsies from mice were taken and stored at 4 °C until 
further used. For DNA isolation, 85 μl of lysis buffer (25 mM NaOH, 0.2 mM EDTA) 
were added to each biopsy and incubated at 95 °C for at least 45 min (or until most 
tissue was dissolved). 85 μl of neutralization buffer (40 mM Tris HCl, pH 8) was 
added and the DNA concentration measured using a NanoDrop (Thermo Fisher 
Scientific). 
Genotyping PCR. In a total reaction volume of 50 μl, 1x green Go-TAQ® 
Flexi buffer (Promega), 0.2 mM dNTP mix (Sigma), 0.2 μM of each primer 
(Microsynth), 1.5 mM MgCl2 (Promega) (for wildtype PCR) or 2 mM MgCl2 (for KO 
PCR), 100 ng template DNA and 1.25 u Go-TAQ® Flexi DNA polymerase 
(Promega) were mixed. To detect the wildtype allele, primers Adprhl2_DF1 (5’-3’ 
GGTTTGGGAAGCAATTTCAAAAAGG) and Adprhl2_ER1 (5’-3’ 
TTGGACGCCAAGGAGTGAGTAT) were used, leading to an expected PCR 
product size of 326 bp. For the detection of the mutant allele containing the exon 
deletion, primer Adprhl2_DF1 and primer Adprhl2_DR1 (5’-3’ 
GAAAGTTTCCCTTCAGAAATCAGGG) were used, leading to an expected PCR 
product size of 532 bp, and the potential amplification of the endogenous wildtype 
allele appearing as a larger band. The PCR program used for both PCRs was initial 
denaturation at 95°C for 2 min, 35-40 cycles of denaturation at 95°C for 30 s, 
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annealing at 58°C for 30 s and extension at 72°C for 1 min, and a final extension at 
72°C for 10 min.  
 
Mouse organ processing for protein isolation and Western blotting 
Protein isolation. Excised mouse organs were snap frozen in liquid nitrogen 
and stored at -80°C. For tissue lysis, ice-cold modified RIPA buffer (50 mM Tris HCl 
pH 7.4, 400 mM NaCl, 1% NP-40, 0.1% Na-deoxycholate, 1 mM EDTA, 1x EDTA-
free protease inhibitor cocktail (Roche)) was freshly prepared, and supplemented with 
40 μM PJ34 and 75 μM tannic acid to inhibit potential ARTD or PARG/ARH3 
activity during lysis. RIPA buffer was added to frozen organs and lysis performed on 
a Tissue Lyser II (Qiagen) at 30 Hz for at least 1x 30 s, further cycles were added 
until respective tissues were fully lyzed. The lysate was incubated on a roller for 30 
min at 4°C, sonicated 3 x 30 s and cleared by high-speed centrifugation. The 
supernatant was supplemented with glycerol to a final concentration of 20%. Protein 
concentration was measured using a Bradford assay (Biorad).  
Western blotting. Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and bands visualized by using IR-Dye-conjugated 
antibodies (1:15’000, LI-COR) and detection by the Odyssey infrared imaging system 
(LI-COR). Antibodies used for Western blotting were diluted in 1% milk in TBST 
(0.05% Tween 20) as follows: α-MAR (1:1’000, homemade, raised in rabbits against 
a chemically ADP-ribosylated H2B-like peptide), α-tubulin (1:10’000, Sigma), α-
ARH3 (1:1’000, custom made, Genosphere Biotech), α-H3 (1:5’000, Abcam), α-
H3K27me3 (1:1’000, Cell Signaling).  
 
Mouse organ processing for mass spectrometric analysis 
Protein isolation. Lysis buffer (6 M guanidine-hydrochloride (Gnd-HCl), 5 
mM tris (2-carboxyethyl)phosphine (TCEP), 10 mM 2-chloroacetamide CAA, 100 
mM Tris pH 8) was preheated to 95°C and directly added to frozen tissue. Upon lysis 
using a Tissue Lyser II (Qiagen) as described above, sample concentration was 
measured using a Bradford assay (Biorad), the samples were diluted with 25 mM Tris, 
pH 8, and digested with trypsin (Promega). The peptide mixture was treated with 
PARG to obtain only MARylated peptides, and the peptides were enriched using a 
macrodomain affinity pulldown as described previously23-25. However, instead of the 
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conventional Af1521, we used an Af1521 mutant from a phage display shown to bind 
ADP-ribosylated peptides with higher affinity (data not shown). Data analysis was 
performed as described in (Abplanalp et al.), using the UniProtKB mouse database 
(taxonomy 256 10090, version 20160902). Mascot 2.5.1.3 (Matrix Science) was used 
for peptide sequence identification. S, R, K, D, E and Y residues were set as variable 
ADP-ribose acceptor sites. Peptides were considered correctly identified only when a 
Mascot score >20 and an expectation value >95% was reached. Venn diagrams were 
plotted using the online tool Venny 2.1.0 (Oliveros, J.C. (2007-2015) Venny. An 
interactive tool for comparing lists with Venn's diagrams, 
http://bioinfogp.cnb.csic.es/tools/venny/index.html). Gene ontology analysis was 
performed using the PANTHER database136.  
 
Cells 
MEF cells from WT and ARH3 KO mice (kindly provided by Joel Moss, 
described in65), mouse ear fibroblasts and MLFs isolated from our WT and ARH3 KO 
mice, as well as 3T3, RAW, and HEK cells (all ATCC) were all cultured in DMEM 
(GIBCO) supplemented with 5% penicillin/streptomycin (P/S) and 10% fetal calf 
serum (FCS).  
  
Cloning of mouse ARH3 constructs  
cDNA of mouse ARH3 was kindly provided by Joel Moss. The ARH3 
sequence was amplified with primers (Microsynth) and cloned into the mammalian 
expression vectors pHA-MEX, pcDNA3.1 or pEGFP using restriction enzymes 
BamHI and XhoI (NEB). Plasmids were sequenced by Microsynth and purified using 
the NucleoBond Xtra kit (Macherey-Nagel) before transfection into 3T3 cells.  
 
Transfection 
Overexpression constructs. 3T3 cells were transfected at 40% confluency. 2x 
BES (50 mM N,N-bis(2-hydroxyethyl)-2-amino-ethanesulfonic acid (BES), pH 6.95, 
280 mM NaCl, 1.5 mM Na2HPO4 in ddH2O) was added dropwise to a mix of plasmid 
DNA and CaCl2, yielding a final concentration of 1x BES, 10 μg/ml DNA and 150 
mM CaCl2), incubated for 3 min at room temperature (RT) and added to the cells 
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dropwise without swirling.  Medium was changed after 6h and cells incubated for a 
total of 48-72h.  
siRNA. 3T3 cells were transfected at 60% with 10 nM final concentration of 
siMock (Allstar Negative Control) or Mm_Adprhl2_1 or Mm_Adprhl2_5 siRNA (all 
from Qiagen) using the Lipofectamine® RNAiMAX Reagent (Invitrogen). The 
transfection solution was prepared according to the manufacturer’s protocol) and cells 
incubated for 48-72h.  
 
Immunofluorescence 
3T3 cells were grown in 24-well plates on coverslips to a confluency of 80-
90% confluency. Cells were fixed with 4% paraformaldehyde in PBS (PFA) for 15 
min at RT and permeabilized with 0.2% Triton X-100 (in PBS) for 10 min at RT. 
After washing with PBS three times, cells were blocked in blocking solution (2% 
BSA, 0.1% Triton X-100 in PBS) for 45 min at RT. Primary antibody α-FLAG (M2) 
(1:1’000, Sigma) or α-HA (1:250, Covance) was incubated for 1h at RT in blocking 
solution. Cells were washed with PBS three times before the addition of secondary 
antibody Cy™3 AffiniPure Goat Anti-Mouse IgG (1:250, Jackson ImmunoResearch) 
in blocking solution for 1h at RT. Cells were washed three times again, and incubated 
for 2.5 min with Hoechst (1:500, Sigma), washed once with PBS, and mounted onto a 
glass slide using VECTASHIELD® mounting medium and fixed with nail polish. 
Images were acquired using an inverted fluorescence microscope at 40×, oil 
immersion (Leica). 
 
FLAG-immunoprecipitation and mass spectrometry 
Immunoprecipitation. Flag-tagged proteins were immunoprecipitated using 
ANTI-FLAG M2 agarose beads (Sigma). Slurry beads were washed three times in 
binding buffer (250 mM HEPES pH 7.9, 2 mM MgCl2, 0.2 mM EGTA, 10% glycerol, 
0.1 mM PMSF, 2 mM DTT, 140 mM NaCl, 0.1 % NP-40, 1 μg/ml leupeptin, 1 μg/ml 
pepstatin, 1 μg/ml bestatin). 500 μg cell lysate was incubated with 30 μl beads in 1 ml 
binding buffer for 2h at 4°C. Beads were washed four times with 1 ml binding buffer. 
Elution was carried out using binding buffer supplemented with 0.150 μg/μl FLAG 
peptide (Sigma) and incubation for 30 min at 4°C.  
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Sample digest and cleanup. Per 30 μl of elution, 200 μl of 8M urea (UA, in 
100 mM Tris, pH 8.0) were added. Samples were loaded onto Amicon Ultra-0.5 ml 
centrifugal filters (Merck) according to the manufacturer’s manual. Once the entire 
sample was loaded, several washing steps were applied. First, 200 μl UA were added,  
then the sample was incubated with 100 μl 0.05 M iodoacetamide for 5 min, then 
washed twice with UA, twice with 0.5 M NaCl, before transferring the filter to a new 
collection tube. Samples were digested on the filter overnight in 0.05 M 
triethylammonium bicarbonate containing trypsin in a 1:50 ratio to protein before 
centrifugation and final acidification to 0.5% trifluoroacetic acid the next day. The 
Functional Genomics Center Zurich (FGCZ) further processed samples.  
 
Silver staining 
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. All following incubations were carried out at RT. The gel was fixed 
for 30 min in 50% methanol and 10% acetic acid. One wash for 15 min in 5% 
methanol was followed by three washes with H2O for 5 min each. The gel was 
sensitized for 2 min in tetrathionate sensitizing solution (0.2 g Na2S2O3 in 1 l of H2O) 
and washed again three times with H2O. The gel was stained with 200 mg AgNO3 in 
100 ml H2O for 25 min. After three 1 min washes with H2O, the gel was developed for 
5-10 min in developing solution (3 g Na2CO3, 50 μl formaldehyde (37%) and 2 ml of 
tetrathionate sensitizing solution in 100 ml H2O). The reaction was stopped for 10 min 
in stopping solution (0.05 M EDTA), and the gel washed and stored in H2O. 
 
Viral transduction 
Lentivirus production. A 10 cm dish of HEK cells was transfected using the 
above protocol with 3.5 μg of the envelope-encoding plasmid pMD.G and 6.5 μg of 
the packaging plasmid CMV delta R8.91 and either 10 μg of the shMock empty 
pLKO.1 plasmid or a construct containing a shRNA targeting murine ARH3 
(pLKO.1, shARH3, TRC0000340923, Sigma). After 6h, 6ml of fresh medium was 
added to the cells. The medium containing the virus was collected after 24h by 
centrifugation through a 0,45 μm cellulose acetate filter.  
Transduction of target cells. RAW cells were infected at a confluency of 50%. 
2 ml medium containing the virus and 4 μg/ml polybrene was added to a 6-well of 
  100 
RAW cells. After 12 h, cells were split and selected using puromycin (3 μg/ml). In 
order to guarantee the knockdown, cells were continuously cultured in the presence of 
puromycin.    
 
Isolation of bone marrow-derived macrophages 
Femur and tibia from WT and ARH3 KO mice were isolated. The bones were 
sterilized with ethanol and both ends cut with a scalpel. Bone marrow cells were 
flushed out using a syringe filled with PBS pH 7.4 containing 10 mM EDTA and 10% 
FCS. Cells were centrifuged for 3 min at 500 g and the pellet resuspended in 1 ml 
ACK Lysis buffer (Gibco), kept on ice for 2 min and centrifuged again. The pellet 
was resuspended in RPMI (Gibco) supplemented with 5% P/S and 10% FCS and 20 
ng/ml mouse m-CSF for five days to stimulate macrophage differentiation.  
 
Ear and lung fibroblast isolation 
Ears and lungs of euthanized WT and ARH3 KO mice were isolated and 
washed with ethanol or PBS, respectively. After drying the tissues, they were cut into 
small pieces and incubated for 90 min at 37 °C in 4 ml (lungs) or 2 ml (ears) lysis 
buffer (150 mM NaCl, 10 mM HEPES, 2 mM CaCl2, 0.1% collagenase and 2.4 U/ml 
dispase, sterile filtered). Cells were centrifuged after addition of 2 ml 0.05 M EDTA 
in PBS for 5 min at 500 g, the pellet resuspended in 5 ml DMEM supplemented with 
5% P/S and 10% FCS and plated. Cells were continuously observed and split when 
getting to 80-90% confluency.  
 
RNA isolation and qPCR analysis 
Cells were washed with PBS once before performing RNA extraction with the 
NucleoSpin RNA II kit (Macherey-Nagel). RNA was quantified with a NanoDrop 
(Thermo Fisher Scientific) and reverse transcribed according to the supplier’s 
protocol (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems). 
Quantitative real-time polymerase chain reactions (qPCR) were performed with 
KAPA SYBR fast (Kapa Biosystems) and a Rotor-Gene Q 2plex HRM System 
(Qiagen). 
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Griess assay 
The amount of NO2- secreted into the cell medium was measured by mixing 
100 μl sample with 100 μl 1% sulfanilamide in 2.5% phosphoric acid (H3PO4) and 
100 μl naphthylethylenediamine dihydrochloride in 2.5% H3PO4. Absorbance at 550 
nm was measured and the amount of NO2- calculated by using measurements of 
NaNO3 standard samples.  
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4 Discussion 
4.1 Summary of the results 
The aim of this thesis was to identify and characterize a ADP-ribosylhydrolase 
able to cleave the linkage between ADP-ribose and the amino acids serine and/or 
lysine, and to characterize this hydrolase in the cellular and organismal context.  
With these studies, we provide evidence that ARH3 is a mono-ADP-
ribosylhydrolase that cleaves the serine-ADP-ribose linkage. ARH3 deficiency (i.e. 
KO of ARH3) increased the basal ADP-ribosylome in MEF cells or the spleen 
(Abplanalp et al., submitted manuscript, and unpublished results, Figures 8 and 
Figure 9). The main targets of ARH3 were nuclear proteins involved in DNA 
packaging, chromatin remodeling and nuclear export (Abplanalp et al., submitted 
manuscript, and unpublished results, Figure 10). Moreover, ARH3 was required for 
the establishment and/or maintenance of the histone modification H3K27me3 in MEF 
cells (unpublished results, Figure 11) and transcriptionally regulated the iNos 
expression, and stimulated the catalytic activity of iNos (unpublished results, Figure 
13 and Figure 14). Initial analyses of the ARH3 KO mouse revealed that ARH3 is 
dispensable for viability and fertility (unpublished results, Figure 5), and that these 
mice have no obvious phenotype, except for a weight gain evidently observed for 16 
week-old mice (unpublished results, Figure 6 and Figure 7).  
 
4.2 ARH3 has OAADPR-, PAR-, and newly also MAR-hydrolase activity 
Previous work reported a PAR- and OAADPR-activity for ARH355,56. A 
mono-ARH activity of ARH3 was excluded, although ARH3 was only tested to 
demodify ADP-ribose-cysteine, -asparagine, and diphtamide56. Here, we identified 
ARH3 as mono-ADP-ribosylhydrolase able to demodify serine residues (Abplanalp et 
al., submitted manuscript). Considering the high degree of homology of ARH3 with 
ARH1 and DRAG, which are both mono-ARHs, it is however not surprising that 
ARH3 is also able to release the terminal protein-bound ADP-ribose additional to its 
PAR- and OAADPR-hydrolase activity. So far, we were not able to dissect a distinct 
amino acids or regions of ARH3 that regulate either the MAR- or the PAR-degrading 
activity.  
The three enzymatic activities of ARH3 could be viewed as ‘enzymatic 
promiscuity’, that is regulated by e.g. PTM of the respective enzyme, substrate 
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binding and/or conformational changes137. To define which ARH3activity is the most 
physiologically most relevant will require further studies. These include the 
crystallization or in silico modeling of ARH3 together with the respective substrates 
to identify specific residues important for binding and/or catalytic activity. Site-
directed mutagenesis followed by in vitro activity assays using recombinant ARH3 
will help solving the structural basis for ARH3’s catalytic activity. Assays to assess 
enzyme kinetics and binding affinity will help resolving which substrates (MAR, 
PAR or OAADPR) are most likely the major targets of ARH3.  
 
4.3 ARH3 is a nuclear serine-mono-ADP-ribosylhydrolase 
Regarding the amino acid specificity of ARH3, we found S to be the major 
demodified ADP-ribose acceptor site in in vitro and in vivo, although we observed 
also a slight increase in lysine and glutamic acid ADP-ribosylation in ARH3 KO 
MEFs and ARH3 KO spleen, the only organ, where we were able to detect an increase 
in MARylation upon ARH3 KO (Abplanalp et al., submitted manuscript, and 
unpublished results, Figure 9). Another group recently also reported that ARH3 
demodifies ADP-ribosylated S, but not ADP-ribosylated E or K in vitro134. Based on 
our data, we do not exclude the possibility that in vivo, ARH3 demodifies additional 
ADP-ribosylated amino acids. Our mass spectrometry workflow might be biased 
towards the detection of serine-ADP-ribosylation, as other groups have shown mainly 
glutamic and aspartic acids to be modified, however using a different enrichment 
method22. Characterising ARH3 and other mono-ADP-ribosylhydrolases on samples 
enriched according to this E/D specific method in combination with label-free 
quantification mass spectrometry, will reveal which hydrolases are capable of 
reverting MARylated glutamic and aspartic acid residues.  
As serine sites are mainly modified by ARTD1 in complex with its auxiliary 
factor HPF126,138, we assume ARH3 as only serine-specific ADP-ribosylhydrolase 
known so far, to be the main regulator of ARTD1-mediated ADP-ribosylation. We 
can however not exclude that potentially other hydrolases are also capable of 
releasing ADP-ribose from serines. Considering the chemical similarities of serines to 
tyrosines (both containing an alcohol group), we speculate that ARH3 is not only able 
to hydrolyze ADP-ribosylated serine residues, but also ADP-ribosylated tyrosines. 
The same should also be considered for the hydrolysis of the ADP-ribose-glutamic 
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acid linkage. Hydrolysis of ADP-ribose from lysines, which harbor an amino-group, 
is more difficult to explain. As lysines are known to be also non-enzymatically 
modified by free ADP-ribose, i.e. glycation139, further experiments investigating in 
vitro demodification of specific peptides modified at lysine residues will be required. 
Additionally, additional evidence for the functional relevance of lysine ADP-
ribosylation in vivo are still required, and studies including KO animals for the 
different mono-ARHs will reveal whether and to which extent, a certain hydrolase is 
responsible for lysine demodification.  The specificity of ARH3 (or other potential 
ADP-ribosylhydrolases) towards a specific amino acid might be tightly regulated 
comparable to the different activities in ARH3 described above, e.g. by other 
posttranslational modifications of the ADP-ribosylhydrolases itself, which might 
influence the conformation of the protein. Alternatively, a co-factor might regulate the 
hydrolase activity, comparable to the HPF1 interaction with ARTD1.  
In our studies, ARH3 primarily localized to the nucleus, more specifically to 
chromatin, when investigated by Western blot of endogenous or immunofluorescence 
of overexpressed tagged ARH3 (Abplanalp et al., submitted manuscript, and 
unpublished results, Figure 12A-12C). The identification of mainly nuclear ADP-
ribosylated proteins in the ARH3 KO spleen samples and the identification of nuclear 
interaction partners strongly support this finding (unpublished results, Figure 10). 
Recently, the Human Protein Atlas Project (HPA) has mapped all human proteins to 
their respective subcellular localization by immunofluorescence, and validated their 
findings using mass spectrometry studies140. These data strongly correlate with our 
findings, confirming that ARH3 is localized in the nucleoplasm in several cell lines 
and with several tested antibodies (www.proteinatlas.org). Other groups provided 
evidence that endogenous ARH3 is localized mainly to the cytoplasm, as well as to 
the nucleus and mitochondria, but to a lesser extent65. Yet, other experiments showed 
that a C-terminally FLAG-tagged ARH3 localized to the mitochondria, due to a 
potential N-terminal mitochondrial signaling peptide present in ARH3141. In the same 
studies, however, immunofluorescence-stainings using a FLAG antibody indicated 
that the main portion of ARH3 resides in the nucleus and not in the mitochondria, 
which was not further discussed by the authors, neither did they confirm co-
localization of ARH3-FLAG with a mitochondrial marker141. Since we did not 
perform an overexpression with C-terminally flagged ARH3 constructs, we cannot 
  105 
fully exclude its mitochondrial localization. Potentially, the N-terminal signaling 
peptide might be required to redirect ARH3 to the mitochondria under specific 
conditions. Based on our findings investigating both endogenous and tagged ARH3 
together with the data from the HPA, a nuclear localization of ARH3 under basal 
conditions is most likely. 
 
4.4 ARH3 demodifies nucleosomes and chromatin-associated proteins  
Unfortunately, not much is known about the cellular function of ARH3, except 
for its involvement in the oxidative stress response65,141. In our studies, ARH3 
demodified ARTD1-ADP-ribosylated histones in vitro, and depletion of ARH3 in the 
spleen resulted in an increased ADP-ribosylation of core histone variants and 
especially H1 (Abplanalp et al., submitted manuscript, unpublished results, Figure 
10). Histones were long known to be ADP-ribosylated18-20,26, however, full reversal of 
this modification has so far not been shown. The mono-ARH activity of ARH3 on in 
vitro modified histone tails provides evidence for a full reversibility of histone ADP-
ribosylation. The molecular role of histone ADP-ribosylation is poorly understood. 
Upon H2O2-treatment histone ADP-ribosylation rather seemed to decondense 
chromatin structures, and was mainly found in vivo associated with heterochromatin 
36,128. It is tempting to speculate that similar to histone methylation or acetylation, 
ADP-ribosylation regulates DNA accessibility or recruits proteins with an ADPr-
binding domain and thus needs to be considered as a new important player in 
chromatin remodeling, subsequently regulating DNA associated processes such as 
transcription, replication and repair. ChIP analysis using an ARH3 antibody or an 
overexpressed tagged ARH3 version would reveal the genomic loci at which ARH3 
resides. Together with ADP-ribose ChAP (i.e. identification of chromatin ADP-
ribosylation), this would reveal at which loci ARH3 activity is most likely important. 
Global changes in the chromatin landscape, specifically targeting active and 
repressive histone marks, could be further investigated by ChIP in WT and ARH3 KO 
cells. ATAC-seq of ARH3 cells would reveal how the accessibility of chromatin is 
regulated by ADP-ribosylation at a genome wide level.  
We identified in the spleen Cbx5 and Lbr as novel targets of ARH3 
(unpublished results, Figure 10). Moreover, we observed a decrease in global 
H3K27me3 in ARH3 KO MEFs, linking ARH3 and potentially its enzymatic activity 
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to heterochromatin formation and/or maintenance (unpublished results, Figure 11). 
Cbx5 and Lbr are part of a complex, although not directly interacting, that binds core 
histones H3 and H4 and anchors them to the nuclear lamina, an interaction lost upon 
acetylation of the histones142. We hypothesize that ADP-ribosylation of either Cbx5, 
Lbr, or the histones might, comparable to acetylation, interfere with their binding to 
the nuclear lamina. ARH3 might thus as part of the Cbx5-Lbr-histone complex, 
demodify the protein complex and regulate binding to the nuclear lamina thus 
assuring the formation and maintenance of H3K27me3. Interestingly, ADP-
ribosylation has already been associated with lamina-associated domains (LADs), 
where ARTD1 interplays with CTCF to associate genomic regions to the lamina for 
controlling their expression dependent on the circadian clock143. Co-IP studies, ChIP 
and ChAP experiments and immunofluorescence imaging for distinct chromatin 
regions might shed light on the exact nuclear localization of ARH3 and its potential 
association with LADs.  
In addition, we identified another newly emerging potential function of ARH3 
in nuclear export, specifically for ribonuclear proteins, since several ARH3 target 
proteins are involved in nuclear export, such as Npm1, found to drive nuclear export 
of ribosomes, as well as ribonucleoproteins itself (unpublished results, Figure 10). 
Additionally, we identified exportin-2, which mediates importin-α re-export from the 
nucleus after cargo substrate release into the nucleoplasm as a binding partner of  
(unpublished results, Figure 12). In vitro studies using recombinant ARH3 would 
reveal whether it is indeed able to demodify the identified targets. Co-IP experiments 
would additionally show whether ARH3 really binds to exportin-2 and other 
identified potential binders.  
 
4.5 Cellular function of ARH3 
The downregulation or depletion of ARH3 in different cell types has provided 
opposite data on LPS-induced iNOS mRNA expression (unpublished results, Figure 
12 and Figure 13). We assume that either ARH3 itself acts as a direct regulator of 
transcription, or as cofactor of a transcription factor. Genetic complementation 
experiments overexpressing the WT or catalytic inactive form of ARH3 in an ARH3 
KO context would reveal whether these effects are dependent on the enzymatic 
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activity of ARH3 or whether ARH3 is an important transcriptional regulator 
independent of its catalytic activity. 
Both shARH3 Raw cells and BMDM from ARH3 KO mice showed a 
decreased or complete loss of iNOS activity (unpublished results, Figure 12 and 
Figure 13). Interestingly, NOS activity has been shown previously to be regulated by 
conformational changes induced by binding to calmodulin144. We hypothesize that 
ARH3 might either bind iNOS directly or might interfere with binding of other 
binding partners of iNOS, e.g. upon removal of the ADP-ribose. ADP-ribosylome 
analysis upon LPS stimulation of shMock and shARH3 RAW cells might reveal 
whether iNOS itself or potential binding partners are ADP-ribosylated and whether 
this is dependent on the presence of ARH3. Additionally, direct binding of ARH3 to 
iNOS could be investigated by co-IP experiments. 
 RAW cell changed their morphology upon LPS treatment, in particular 
by flattening their shape, building vacuoles and protruding processes. These changes 
were more dramatic in shARH3-treated cells compared to shMock (unpublished 
results, Figure 13) and are in line with already published data, where treatment of 
RAW cells with LPS caused similar morphological effects145. Further investigations 
are required to address, what function these vacuoles have and how they are regulated 
by ARH3. As the stimulation of RAW cells was shown to enhance accumulation of 
triglycerides146, vacuoles observed in our cells might contain fat, which could be 
confirmed by checked markers for lipid accumulation, such as oil red staining.       
 
4.6 The functional role of ARH3 at the organismal level 
While an initial necropsy of ARH3 KO and WT mice did not point at specific 
abnormalities, at 16 weeks of age, we observed female ARH3 KO mice to be 
significantly heavier compared to their WT counterparts (unpublished results, Figure 
7). Interestingly, ADP-ribosylation has been implicated as a regulator of adipogenesis. 
ARTD1 inhibition or ARTD1 KO impaired adipocyte differentiation (i.e. 
adipogenesis) under a high-fat diet147. Moreover, ARTD1 stimulated in vitro the 
differentiation of fibroblasts to adipocytes by binding to and PARylating PPARγ2, 
leading to PPARγ2-target gene expression and terminal adipocyte differentiation111. 
Consequently, we hypothesize that feeding ARH3 KO mice with a high-fat diet would 
further accelerate the phenotype observed under conventional chow diet resulting in 
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even stronger increased body weight gain and fat content of these mice. ARH3 might 
directly demodify PPARγ2 and repress PPARγ2-target gene expression, thereby 
counteracting ARTD1’s function and act as a repressor of adipogenesis. Further 
analyses using the ARH3 KO mouse and si- or shRNA-mediated knockdown of ARH3 
during in vitro differentiation will reveal whether ARH3 is the main player 
counteracting ARTD1 in the context of adipogenesis. A recent study has linked 
regulatory T cells (Treg) to adipogenesis in that Tregs were shown to be induced upon 
high-calorie diet or cold exposure and were necessary to keep the adipose tissue 
functional148. It would be interesting to see how adipose tissue of ARH3 KO mice 
would react to these stimuli.  
Single gene expression analysis using ARH3 KO MEFs and fibroblast of 
different tissues, revealed that ARH3 regulates, besides other genes, also iNOS 
expression, an NF-κB target gene. On the one hand, ARH3 repressed iNOS 
transcription upon LPS treatment in several cell lines (i.e. 3T3 and RAW cells, as well 
as BMDM and mouse ear fibroblasts), but on the other hand stimulated iNOS 
catalytic activity (i.e. RAW cells and BMDM) (Figure 13 and Figure 14). This might 
be due to two independent mechanisms. ARTD1 has been implicated in the regulation 
of the TLR4-mediated response to LPS via NF-κB88,109, and considering the MAR and 
PAR-degrading function of ARH3 and its involvement in iNOS regulation, we 
speculate that ARH3 hydrolyzes ARTD1-mediated ADP-ribosylation in TLR4-
mediated LPS signaling. We speculate that in animal models of e.g. LPS-induced 
septic shock or Salmonella typhimurium infection, where ARTD1 KO mice showed a 
rather protective (i.e. slow response) phenotypes106,149, ARH3 KO mice, due to 
enhanced ADP-ribosylation levels, might show a stronger and enhanced reaction 
compared to ARTD1 KO mice. 
 
4.7 The ARH3 KO mouse does not phenocopy the PARG KO mouse 
Our necropsy of organs and tissues of adult ARH3 KO mice revealed no major 
morphological differences. Also, we were only able to detect by Western blotting 
ARH3 protein in the lymph node and the spleen (Figure 8). Considering the published 
RNA sequencing data from mice, ARH3 mRNA is ubiquitously expressed, with the 
highest expression levels in immune cells, e.g. in myeloid progenitor cells and 
macrophages (biogps.org). This observation fits well with our observation, as these 
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cell types reside in spleen and lymph nodes, indicating a potential function of ARH3 
in immunity. ARH3 protein was not detected with our antibody in the liver, the 
kidneys, and the heart, indicating that either, our antibody is not specific enough, or 
that the half-life time of the mRNA or the protein is altered in these organs.  
ARH3 KO mice are viable, fertile and do not show any obvious differences 
from WT mice in the first few weeks after birth. Considering that both ARH3 and 
PARG localize to the nucleus and both degrade PAR, it seems likely that their KO 
would lead to similar phenotypic outcomes. Accordingly, it has been reported that a 
KO mouse missing the nuclear 110 kDa PARG isoform is viable150. It would be 
interesting to test whether a complete KO of nuclear PAR-degrading enzymes, i.e. a 
double KO of ARH3 and the 110kDa PARG isoform, would be viable. Considering 
the massive accumulation of PAR expected in these mice, potentially leading to a 
massive depletion of NAD+, we would expect these mice to be embryonically lethal. 
Except for the ARH1 KO mouse, which is viable, but shows an enhanced occurrence 
of different tumors compared to WT mice60, no other model of a mono-ARH has been 
described so far. Little is known about the in vivo degradation of OAADPR, and 
although mammalian nucleoside diphosphates linked to x (NUDIX) hydrolases as 
well as macrodomains are known to hydrolase OAADPR in vitro, no known NUDIX 
or macrodomain member has been identified to degrade OAADPR in vivo, except for 
the NUDIX hydrolase Ysa1 from Saccharomyces cerevisiae151.   
We reason that ARH3 KO mice do not show major morphological differences 
when compared to WT for several reasons. The lack of ARH3 as mono-ADP-
ribosylhydrolase, might be compensated by other nuclear mono-ARHs (e.g. 
macrodomains), while PARG would be able to compensate for the missing PAR 
hydrolase activity of ARH3. Additionally, considering its potentially restricted 
expression pattern on the protein level, ARH3 activity might only be physiologically 
relevant in specific tissues  
Data from our and one other group show that a lack of ARH3 in cultured cells 
leads to enhanced ADP-ribosylation levels (Abplanalp et al., submitted manuscript, 
and134), however, data on ARH3 KO tissue have so far been missing. Own initial mass 
spectrometric analysis of spleens isolated from WT and ARH3 KO mice identified 
under basal levels 40 proteins to be only ADP-ribosylated in the absence of ARH3 
(Figure 10). Although there is also an extensive basal ADP-ribosylome observed in 
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ARH3 KO spleens, the spleen morphology seemed macroscopically not to be affected, 
indicating that an enhanced basal ADP-ribosylome does not alter the cell fitness 
drastically, and that organ and tissue function is likely independent of ARH3 
enzymatic activity. Moreover, it seems that neither PARG nor any other mono-ADP-
ribosylhydrolase would compensate ARH3’s function under basal conditions in the 
mouse. Assuming a potential role of ARH3 in chromatin modeling (see above), it 
might be that under basal conditions, presence or absence of ARH3 does not 
functionally contribute in a fully differentiated and developed cell. However, we 
would assume that upon stress, those mice might suddenly show differences 
compared to WT (see also above). Different experiments, such as high-fat diet or 
bacterial challenges as mentioned above, might reveal a pathophysiological role of 
ARH3. 
 
4.8 Clinical relevance 
Based on our submitted and unpublished data ARH3 seems to play a much 
broader role and has so far been underestimated in various ways. Potentially, the role 
of ARH3 in both physiological and pathological conditions is more important than so 
far expected and further studies specifically targeting the aspects described above 
might help to further elucidate how ARH3 regulates ADP-ribosylation and cellular 
processes. With a potential function in adipogenesis and the immune response, ARH3 
might be an interesting target for therapeutic intervention. Additionally, having in 
mind that several other MAR erasers as well as ARTD1 are implicated in various 
cancers, it is not unlikely that ARH3 might plays a role in cancer development as 
well. Whether ARH3 has an additional role as a structural component, e.g. by being 
part of protein complexes, fulfilling a function independent of its enzymatic activities 
needs further analyzed. Dissecting these two possibilities (ARH3 activity vs. ARH3 
presence only) could be achieved by genetic complementation of cells with WT and 
enzymatic ARH3 mutants or by generating mice expressing an inactive ARH3 using 
CRISPR/Cas9 knockin models. 
We observed that ARH3 is inhibited by the known PARG-inhibiting agent 
tannic acid (Abplanalp et al., submitted manuscript). Several rhodanine-based PARG 
inhibitors (RBPI) were published to selectively inhibit PARG but not ARH3, whereas 
adenosine diphosphate (hydroxymethyl)pyrrolidinediol (ADP-HPD) inhibits PARG 
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and ARH3 PAR-degradation, with a higher affinity for ARH3152. To dissect which 
cellular function of ARH3 depends on its hydrolase activity, it will be crucial and 
important to develop a specific ARH3 inhibitor. Screening available compound 
libraries and identifying small molecules against ARH3 in vitro, e.g. in radioactivity 
assays or a cell-based assay using an immunofluorescence readout, could help to 
identify a potent ARH3 inhibitor. Some of them maybe even inhibit either the PAR-, 
MAR, or OAADPR-degrading function separately and allow dissecting their 
contribution in the cellular context.  
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6 Abbreviations 
ADP Adenosine diphosphate 
ADP-HPD Adenosine diphosphate (hydroxymethyl)pyrrolidinediol 
AHR Aryl hydrocarbon receptor 
AMP Adenosine monophosphate 
APLF Aprataxin and PNK-like factor  
ARH1 ADP-ribosylarginine hydrolase 
ARH3 ADP-ribosylhydrolase 3 
ARNT AHR nuclear translocator 
ART Adenosine diphosphate ribosyltransferases 
ARTC Adenosine diphosphate ribosyltransferase, cholera-toxin like 
ARTD Adenosine diphosphate ribosyltransferases, diphtheria toxin-like 
BAL B-aggressive-lymphoma 
bp Base pair 
BRCA1/2 Breast cancer 1/2 
BRCT domain Breast cancer gene 1 C-terminal domain 
cADPR Cyclic adenosine diphosphate ribose 
ChAP Chromatin affinity precipitation 
ChIP Chromatin immunoprecipitation 
CHFR Checkpoint with forkhead and ring finger domains 
CHK1 Checkpoint kinase 1 
CoaSt6 Collaborator of STAT6 
DNA Deoxyribonucleic acid 
DRAG Dinitrogenase-activating glycohydrolase  
DRAT Dinitrogenase reductase ADP-ribosyltransferase 
DSB Double-strand break 
DTT Dithiothreitol 
E Glutamic acid 
EThCD Electron-transfer/higher-energy collision dissociation 
FHA domain Fork-head associated domain 
H Histidine 
H1 Histone 1 
H2A Histone 2A 
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H2B Histone 2B 
H3 Histone 3 
H4 Histone 4 
HCD Higher-energy collision dissociation 
HDAC Histone deacetylase 
K Lysine 
LPS Lipopolysaccharide 
MACROD1 Macrodomain containing 1 
MACROD2 Macrodomain containing 2 
MAR Mono-ADP-ribose 
MARylation Mono-ADP-ribosylation 
MEF Mouse embryonic fibroblasts 
MLF Mouse lung fibroblasts 
mRNA Messenger ribonucleic acid 
MS Mass spectrometry 
MVP Major vault protein 
NA Nicotinic acid 
NAD+ Nicotinamide adenine dinucleotide 
NAM Nicotinamide 
NAMPT Nicotinamide phosphoribosyltransferase 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NHEJ Non-homologous end joining 
NMNAT Nicotinamide mononucleotide adenylyltransferase 
NR Nicotinamide riboside 
OAADPR 2’-O-acetyl adenosine diphosphate ribose 
OB-fold Oligonucleotide/oligosaccharide-binding fold 
PAR Poly-ADP-ribose 
PARG Poly-ADP-ribose glycohydrolase 
PARP Poly-ADP-ribose polymerase  
PARPi PARP inhibitor 
PARylation Poly-ADP-ribosylation 
PBM Poly-ADP-ribose-binding motif 
PBZ PAR-binding zinc finger 
  120 
PIN domain PilT protein N-terminus domain 
PPARγ2  peroxisome proliferator-activated receptor 2 
PPRE PPARγ2 response elements  
PTM Post-translational modification 
R Arginine 
RBPI Rhodanine-based PARG inhibitor 
RNA Ribonucleic acid 
RRM RNA recognition motif 
S Serine 
shRNA Short hairpin RNA 
siRNA Small hairpin RNA 
SSB Single-strand break 
SUMO Small ubiquitin-related modifier 
TARG Terminal ADP-ribose glycohydrolase 
TCA Trichloroacetic acid 
TCCD 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
TEP1 Telomerase-associated protein 1 
TH2 T helper cell 2 
TLR4 Toll-like receptor 4 
UPR Unfolded protein response 
W Tryptophan 
Y Tyrosine 
ZF Zinc finger 
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